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The x-ray crystal structures for the GTP-bound forms of the small G protein 
Cdc42 and its constitutively activated isoform, Cdc42 (Q61L), were previously 
unkown. The mechanism for the activation event has been largely assumed based on 
x-ray crystal structures for effector-bound-Cdc42 complexes as well as mechanisms 
for activation for other small G proteins such as Ras. 
 We used x-ray crystallography, tryptophan fluorescence, and 31P-NMR to 
study the specific activation event for Cdc42. The x-ray crystal structure revealed a 
signaling-active GTP-analog-bound Cdc42 conformation that was virtually identical to 
the conformation for signaling-inactive GDP-bound Cdc42 (1ANO). It was further 
revealed through the use of tryptophan fluorescence, as well as 31P-NMR, that binding 
of an effector protein played an important part in inducing a conformational change 
that resulted in the fully activated structure usually associated with activated G 
proteins. 
 Conversely, we used x-ray crystallography to reveal that the constitutively 
activated isoform of Cdc42, Cdc42 (Q61L), did not require an effector protein to adopt 
a fully activated structure. 31P-NMR results confirmed these findings and also revealed 
that the GTP-analog, GMP-PCP, behaved similarly to the physiologically relevant 
 nucleotide, GTP, during the activation event. 
 Overall these findings imply that a spectrum of activation mechanisms exist 
for small G proteins where, on the one end, an effector protein is required to induce 
the proper activated conformation (i.e. Cdc42), and on the other end, GTP binding is 
sufficient to drive the G protein to the fully activated structure (i.e. Ras). 
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Chapter I 
Introduction 
 
G Proteins: Historical perspective 
In order to fully appreciate G proteins and their overall contribution to our 
understanding of biology, it is important to start from the very beginning. Arguably, 
the beginning of G protein research can be traced back to the discovery of cyclic AMP 
as a second messenger by Earl Sutherland, for which he received the Nobel Prize in 
1971.  
In the early 1950’s a lot of attention was being paid to glycogen metabolism by 
biochemists. At that time, scientists had already determined that glycogenolysis was 
the ultimate outcome of the hormones epinephrine and glucagon in the liver. Based on 
the work of Carl Cori and others, three enzymes involved in the pathway were 
elucidated. Sutherland and Cori came to the conclusion that the enzyme named 
phosphorylase was the rate-limiting enzyme in the reaction and that the hormones 
glucagon and epinephrine were working by increasing the enzyme’s activity (1). An 
important discovery was made when they found that if they separated membrane 
fractions from the cytosol, they lost the ability to stimulate phosphorylase with 
hormones. However, when they added the membranes back, they were able to recover 
activity. Perhaps more important was the discovery that incubating membranes with 
hormone prior to heat-inactivation, could still activate phosphorylase when the 
membrane fraction was recombined with the cytosol. This lead these investigators to 
look for a heat-insensitive intermediate which resulted in their discovery of cyclic 
AMP. The membrane activity that converted ATP to cyclic AMP was then called 
Adenyl Cyclase (referred to as AC hereafter) and later changed to Adenylyl Cyclase or 
Adenylate Cyclase to be more chemically correct. 
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At this time a number of laboratories became interested in the mechanism of AC 
regulation. It was previously known that a number of different hormones both 
positively and negatively regulated AC and that the hormones all worked on a fixed 
pool of AC instead of each hormone activating its own AC. It was also shown that the 
hormone receptor and AC were two distinct entities that could be resolved and highly 
purified. What was less certain was how the hormone-receptor complex regulated AC 
or if there were more proteins involved.  
The first insights into AC regulation that lead to the discovery of G proteins came 
from Martin Rodbell for which he, together with Alfred Gilman, was also awarded the 
Nobel Prize. Rodbell, Birnbaumer and their colleagues noted that in the presence of 
ATP, the hormone glucagon was able to bind to its receptor much faster but was also 
released from the receptor much more quickly (2). The major breakthrough came with 
the realization that the ATP being used in the AC activity assays was contaminated 
with other nucleotides, notably GTP. The question then arose as to what is the effect 
of GTP on the ability of glucagon to stimulate AC activity? Rodbell and colleagues 
synthesized App(NH)p ( a non-hydrolyzable ATP analog) and assayed glucagon’s 
ability to activate AC. They found that App(NH)p did not stimulate AC unless GTP 
was present in the buffer at concentrations comparable to what was necessary for 
regulating the hormone-receptor (3). This was the first real evidence of a 
“Transducer”, as Rodbell had called it, that mediated the signal from the hormone-
receptor to AC. 
Rodbell and his colleague Yoram Salomon went on the show that synthesized 
Gpp(NH)p could induce the activation of AC, even in the absence of hormone 
although the hormone greatly increased the rate of activation (4). Another intriguing 
finding was that Gpp(NH)p showed prolonged and substantiated activation of AC, 
much greater than with hormone and GTP alone (5). These findings suggested that 
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GTP was acting at a stage after the hormone-receptor interaction and before the 
stimulation of AC. 
In the latter half of the 1970’s it was discovered that hormones like epinephrine 
and glucagon were acting to displace bound GDP in favor of GTP (6). This was 
subsequent to the finding that these hormones could increase the hydrolysis of GTP to 
GDP (7).  From this work, Cassel and Selinger put forward the idea that the hydrolysis 
of GTP to GDP and Pi was the mechanism of shutting down the signaling system 
whereas the binding of GTP in favor of GDP was responsible for activating the 
system. At the time, scientists were calling the GTP-binding entity the regulatory unit 
of AC which was distinct from the catalytic unit but not necessarily separate. The 
possibility that these units represented distinct proteins emerged when investigators 
looked into the ability of hormones to inhibit AC activity. The discovery of adenosine 
receptors that required GTP to inhibit AC made it more convincing (8) and Rodbell 
went on to call the purported GTP-binding units Ns and Ni for nucleotide-binding 
stimulatory proteins respectively (9). 
At about the same time, (i.e. the late 1970’s), work by Gilman and colleagues was 
starting to show direct proof of a separate nucleotide-binding protein that was 
necessary for the function of the AC system. These investigators were trying to 
reconstitute AC activity in vitro by using a variant of S49 lymphoma cells called cyc- 
because it was thought to be deficient in AC. They found that if they prepared a 
detergent extract from wild-type S49 cells, and heat inactivated the AC activity at 
37˚C, they could recombine it with a detergent extract from cyc- cells and restore AC 
activity (10). However, they noted that if they incubated the cyc- extract at 30˚C and 
recombined it with the wild-type extract, they lost AC activity. They postulated that 
the two factors being lost in the wild-type and cyc- heated extracts might be the same. 
In contrast, they found that if wild-type extracts were heated at 50˚C and recombined 
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with cyc- extracts, AC activity was lost over time. Incubation with NaF or Gpp(NH)p 
increased the stability of a thermostabile factor indicating its ability to bind guanine 
nucleotides. This led Gilman and colleagues to propose that there were two factors 
responsible for the activation of AC. The heat labile factors were sensitive to protease 
cleavage and N-ethylmaleimide indicating they were both proteins. Soon after this 
work, Gilman and his colleagues concluded that the “thermolabile” protein in both the 
wild-type and cyc- extracts was the catalytic domain of AC (11). Furthermore, 
combining extracts from cyc- cells containing the thermolabile protein with extracts 
that contained the thermostabile components, but lacked the β-adrenergic receptor, 
reconstituted the epinephrine-sensitive AC activity. Therefore, the cyc- cell lines were 
not deficient in AC but rather lacked the regulatory component, which interacted with 
guanine nucleotide. 
A more direct approach of discovering the GTP-binding factor was under way at 
the same time by Thomas Pfeuffer. Pfeuffer was able to covalently label the GTP-
binding activity in pigeon erythrocyte membranes and resolve it from the AC (12). 
Additionally, he was able to remove the GTP-binding fraction from the catalytic 
fraction by GTP-Sepharose affinity chromatography. The flow-through lacked 
detectable AC activity in the absence of the GTP-binding fraction. Upon elution of the 
GTP-binding fraction with GTP, he was then able to reconstitute AC activity by 
recombining the fractions. 
Gilman and his colleagues eventually succeeded in purifying to homogeneity the 
GTP-binding protein in 1980 (13). They named this GTP-binding protein Gs and 
originally suggested that it contained two subunits, which they named α (Mr ~ 45 kDa) 
and β (Mr ~ 35 kDa). The α subunit bound nucleotide and could stimulate AC activity 
in the cyc- cell lines as well as another cell line named unc which did not exhibit 
hormone-stimulated AC activity although AC in these cells could be directly activated 
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by G proteins. Later it was recognized that heptihelical receptor-associated G proteins 
are actually heterotrimeric after the discovery that the γ subunit (Mr ~ 9 kDa) remains 
constitutively associated with the β subunit under all non-denaturing conditions (14). 
The final conclusive evidence was supplied by Rick Cerione and his colleagues 
who were able to purify all three components of the β-adrenergic receptor-coupled AC 
system and reconstitute them in lipid vesicles (15). These investigators showed that 
AC alone was unresponsive to activation by GTP, however, upon addition of what is 
now known as Gαs with βγ, the GTP-dependent activation was restored but not 
responsiveness to hormone. Addition of the β-adrenergic receptor then fully returned 
hormone sensitivity. Thus, for the first time there was indisputable evidence for a three 
component system being the biologically relevant signaling pathway for cAMP 
formation (Fig. 1.1). 
Since then there have been numerous discoveries about what are now collectively 
called G proteins and their roles in biological systems. It is now recognized that there 
are roughly 1000 GPCRs (G Protein coupled receptors) encoded in the mammalian 
genome (16) and more than 20 heterotrimeric G protein α subunits corresponding to 
16 gene products (17). Additionally, RGS (Regulators of G protein Signalling) 
proteins were discovered, as reviewed by Birnbaumer, that stimulate the GTPase 
activity of the Gα subunit, thereby shutting off the signal in a timely manner (18). 
Even more surprisingly, it has been shown that the Gβγ dimer can act as a signaling 
unit separate from the Gα subunit, in a variety of different systems (18). 
Heterotrimeric G proteins are involved in most vital functions in the human body such 
as glycogen metabolism, cardiac contractions, smell, taste, and vision just to name a 
few. They have also been implicated in a number of different disease states such as 
cancer, diabetes, and cholera (18,19). However, the story does not end with 
heterotrimeric G proteins. Around the same time that people were starting 
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Figure 1.1 Heterotrimeric G Protein Three Component System. Pulled from 
Hamm, HE and Oldham WM, Structural Basis of Function in Heterotrimeric G 
Proteins. Quarterly Reviews of Biophysics, 2006. An agonist (yellow) binds a 
Heptihelical receptor (R*) which then activates the G protein by stimulating the 
exchange of GTP for GDP on the Gα subunit (α). The β,γ-subunits dissociate from the 
Gα which is free to interact with downstream effector proteins (E). The system is 
turned off by hydrolysis of GTP to GDP which is facilitated by an RGS protein 
(Regulator of G protein signaling). Once turned off, the Gα subunit reassociates with 
the β,γ subunits and is able to bind receptor again. In many cases, the β,γ subunits can 
interact with their own effector proteins and contribute to cell signaling.   
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to recognize the importance of heterotrimeric G proteins in second messenger systems, 
discoveries were made that lead to the understanding of the importance of a new class 
of G proteins, namely the Ras-like small G proteins. 
 
 
Ras discovery and function: 
 Small G proteins gained prominence in the early 1980s with the discovery that 
the transforming agent of the Harvey and Kirsten strains of rat sarcoma virus was a 
small G protein named Ras (rat sarcoma) (20,21). Interest in Ras intensified when it 
was discovered to be involved in a number of human cancers (22). It was determined 
that the oncogenic forms of Ras were commonly mutated at positions 12, 13, 59, and 
61, with the majority of mutations occurring at position 12. Mutations at those 
positions were found to inhibit Ras’s GTPase activity and thus rendered it 
constitutively active (as reviewed by Barbacid, 1987). 
 Since that time the family of small G proteins has grown to over 150 members 
with orthologs in most animal species (23). Virtually all G proteins share a similar 
GTPase cycle whereby exchange of GDP for GTP by a GEF protein activates the G 
protein and hydrolysis of GTP to GDP and Pi catalyzed by a GAP protein deactivates 
it (Fig. 1.2). Ras is considered the archetype of the small G protein family due to its 
minimal structure based on sequence and structural alignments. This minimal 
architecture is also homologous to the GTP-binding core of heterotrimeric Gα subunits 
and is considered the minimum structural unit needed to bind guanosine nucleotides 
(Fig 1.3). 
 The most studied and thus best-understood function of Ras is its involvement 
in mitogenic signaling which leads to cancer if unregulated. Ras is a key component in 
most growth factor-stimulated signaling pathways that originate at the cell surface and 
 8
  
 
 
 
 
 
 
 
Fig. 1.2 GTPase Cycle. G proteins are in an inactive “off” state when bound to GDP.   
Activation takes place typically through a GEF, which helps kick out the GDP in favor 
of GTP which is at a higher concentration in the cell. In the heterotrimeric G protein 
system, the GEF is the heptihelical receptor. The G protein is then able to interact with 
downstream targets and transduce a signal. The G protein is turned “off” by a GAP 
(small G proteins) or an RGS (in the case for Heterotrimeric G proteins) which 
accelerates the G protein’s own intrinsic GTP hydrolytic activity. In a few cases, a 
GDI can bind to the G protein and prevent nucleotide exchange and/or hydrolysis.   
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culminate in the nucleus. In fact, Ras is known to not only regulate cell proliferation, 
but to also participate in signaling pathways involved in apoptosis, differentiation, and 
morphologic rearrangements (24).  
Much is now known about the activation of Ras and how this stimulates signals 
that are transmitted to the nucleus. The most common method for Ras activation is 
through receptor tyrosine kinases (RTK). Receptor tyrosine kinases are integral 
membrane proteins which have 3 main domains, an extracellular ligand-binding 
domain, a single transmembrane helical domain, and an intracellular tyrosine kinase 
domain. These receptors are activated by an external signal, usually a peptide, which 
stimulates their dimerization. This in turn results in the auto-phosphorylation of 
tyrosine residues within the cytoplasmic domain which recruit a number of signaling 
molecules to the receptor (25).  
Receptor tyrosine kinase activation of Ras occurs through SOS (Son of Sevenless), 
which is a guanine nucleotide exchange factor (GEF) specific for Ras. SOS is 
recruited to the plasma membrane upon activation of RTKs through a constitutive 
interaction with an adaptor protein called Grb2 (25). Adaptor molecules such as Grb2 
can interact with phosphorylated tyrosine residues through specialized domains such 
as SH2 (src homology domain) or PTB (phosphotyrosine binding) domains. Grb2 
associates with the activated receptor, bringing SOS along with it, through interactions 
with Grb’s SH2 domain. 
Ras, which is attached to the plasma membrane through a farnesyl group on its 
carboxy terminus, is activated by SOS through a positive feedback mechanism (25). 
SOS resides in an autoinhibited state which is able to bind Ras – GDP at an allosteric 
site separate from the catalytic site (26). Binding of Ras – GDP releases some of the 
autoinhibition in SOS and allows for the formation of Ras – GTP. Activated Ras is 
then able to bind with higher affinity to the same allosteric site previously occupied by 
 11
  
 
 
 
 
 
 
 
 
Figure 1.3 Minimal GTP-binding domain of Ras Compared to Transducin. Ras 
(top) is composed of 6 β-sheets (red) and 5 α-helices (blue). Switch I and II are 
depicted in green and are the sites of structural rearrangement during activation of the 
protein. Transducin (bottom) has the same basic GTP binding domain as Ras although 
with 4 insertions, one of which is an N terminal helical domain depicted in aquamarine 
blue. 
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Ras – GDP and elicit full activation of SOS (27,28).  
Ras has multiple targets that feed into a number of different pathways with perhaps 
the most important for cellular transformation being its interaction with the Raf (for 
Rapidly growing fibrosarcomas) kinases. Raf family members are part of a highly 
conserved MAPK (Mitogen activated protein kinase) pathway, which ultimately leads 
to regulation of transcription in the nucleus. All MAPK pathways are comprised of a 
MAPK which is activated by phosphorylation from a MAPKK (MAPK kinase) which 
itself is activated by phosphorylation from a MAPKKK (MAPK kinase kinase) (as 
reviewed by (29)). Raf is part of the ERK1-2 (Extracellular signal-regulated kinase) 
pathway which is involved in cell motility, proliferation, differentiation, and survival 
(30). The MAPKKK, Raf, becomes activated by an intricate process that is not yet 
fully understood. It then activates MEK1/2 (also known as MAPK and ERK kinase), 
which in turn activates ERK, the MAP kinase. ERK has a number of substrates 
including RSK (p90 ribosomal S6 kinase), MSK (mitogen and stress activated kinase), 
and MNK (MAPK interacting kinase), as well as cell attachment and migration 
proteins including paxillin, focal adhesion kinase and calpain, and finally the 
transcription factors Elk 1, c-Fos, c-Myc and Ets domain factors amongst others (30). 
Activation of C-Raf (also known as Raf-1) is the best understood of the Raf 
homologues and appears to share a similar mechanism of activation to A-Raf and B-
Raf. Briefly, Ras recruits Raf to the plasma membrane where it becomes activated by 
a combination of interactions with Ras and other proteins, the plasma membrane, and 
phosphorylation/dephosphorylation at multiple sites (31). This complex regulation of 
both Ras and Raf, and by extension, the ERK pathway, underscores the importance of 
these proteins in normal cellular functions. In fact, mutations in Ras have been found 
in 15% - 30% of all human cancers, ERK is hyperactivated in ~30% of cancers, and 
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Raf has been found to be mutated to large degrees in thyroid, ovarian, and colorectal 
cancers (31). 
Raf is not the only Ras effector that can lead to cellular transformation however. 
Another Ras effector, PI3K (Phosphatidylinositol 3-kinase), is a heterodimer 
consisting of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit and is 
responsible for generating phosphoinositides phosphorylated at the 3΄ position such as 
the second messanger PIP3 (phoshpatidylinositol (3,4,5) P3). Ras can bind and 
activate the p110 catalytic subunit of PI3K which then converts PIP2 to PIP3, as 
reviewed by (32), at the plasma membrane. PIP3 then recruits AKT, a serine/threonine 
kinase, to the plasma membrane by interacting with its PH (Pleckstrin homology) 
domain. Once recruited, AKT becomes activated by phosphorylation at two sites by 
PDK1 and PDK2 (3-Phosphoinositide-dependent protein kinase-1 and 2). 
Subsequently, it is able to interact with downstream effectors that control cell survival, 
proliferation, and growth. Constitutive activation of this pathway has also been shown 
to lead to cancer.  
Ras is not the only G protein that plays an important role in human cancers 
however. As mentioned previously, there are over 150 different small G proteins and 
many of them, if mutated, can cause cellular transformation. Small G proteins are 
classified into 5 different families based on sequence and functional similarities. The 5 
families are the Rho, Rab, Arf, Ras, and Ran families. Each G protein family shares 
structural and mechanistic similarities with each other but often perform 
physiologically distinct functions. There is however, a lot of crosstalk between G 
protein pathways, which adds to the complexity of the system.  
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Rab and Arf cellular functions 
The Rab (Ras related in brain) and Arf (ADP-ribosylation co-factor) families of G 
proteins are involved in anterograde and retrograde cellular trafficking from the ER 
through the golgi to the endosome and plasma membrane. Both Rab and Arf families 
are essential to eukaryotic cells and are required for cellular trafficking (33). The Arf 
family consists of sub-family members Arf, Arl (Arf-like), Arp (Arf-related proteins) 
and the less closely related Sar (Secretion-associated and Ras-related) proteins (34). 
The most well understood function of Arf proteins is recruitment of coat proteins 
required for coated vesicle trafficking (24). Arf is activated by a GEF located on the 
membrane compartment, and then recruits coat protein complexes such as COP (Coat 
proteins) I, COP II, or clathrin. After the budding of the vesicle, a cytosolic GAP 
(GTPase activating protein) catalyzes the hydrolysis of GTP to GDP which allows Arf 
to disengage from the vesicle. This leads to the eventual pinching off of the coated 
vesicle which is trafficked to another compartment (24).  
Currently, our knowledge of Arf and its family members is rather limited. Only 
Arl1 and the Sar proteins have been shown to function in membrane trafficking (34). 
Arl4 has a possible role in the nucleus while Arf 6 is involved with cell migration and 
lamellipodia formation. Little is known about other Arf proteins however, leaving 
open the possibility for novel functions (34).  
Rab G proteins are the most numerous of all the small G proteins. More than 60 
mammalian Rab proteins have been identified. They are localized primarily to the 
golgi and endosomal compartments where they function as regulators of vesicular 
trafficking. Trafficking can be divided into four essential steps which include budding, 
transport, tethering, and fusion (35). Evidence points to a function for Rab proteins in 
all of these events as well as cargo sorting and vesicle formation (36). Rab proteins 
function by making certain that the right cargo is targeted to the right compartment.  
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Like all Ras-like G proteins, Rab proteins cycle between an inactive GDP-bound 
form and an active GTP-bound form (see Fig. 1.2). This GTP-GDP cycle is controlled 
by GEF and GAP proteins specific for Rab family members. In addition, Rab proteins 
undergo a membrane attachment and extraction cycle which is partially coupled to the 
nucleotide cycle (33,36). Inactive prenylated Rab proteins are sequestered in the 
cytosol by a GDI (Guanine-nucleotide dissociation inhibitor) that preferentially binds 
the inactive (GDP-bound) Rab.  This is a common feature among a number of other 
small G proteins including members of the Rho family. Rab insertion into membranes 
is facilitated by a GDF (GDI displacement factor) which catalyzes the release of the 
Rab protein from the GDI, enabling its insertion into the membrane (37). Tight 
binding to membranes is imparted by a feature specific for most Rab proteins, 
specifically two C-terminal cysteins modified by geranylgeranylation instead of only 
one (33).  
 
Ran GTPase Overview 
 Ran (Ras-related nuclear protein) GTPases are the only Ras-like proteins that 
lack post-translational lipid modifications. In addition, unlike other members of the 
family, they are found mostly in the nucleus. Ran is the product of only one gene in 
some cell types but two or more highly related Ran genes have been found in other 
cells (38). Even so, Ran is one of the most abundant proteins in eukaryotic cells. 
Currently, Ran is known to function in two crucial cellular processes, nuclear 
transport, and mitosis. Nuclear transport is the most well understood function of Ran 
and many details of its involvement have been discovered. As reviewed in (39), 
molecules larger than 40 kDa are actively transported across the nuclear envelope 
through NPCs (Nuclear Pore Complexes). Cargo proteins containing a NLS (Nuclear 
Localization Signal) bind to importin-α which in turn binds to importin-β in the 
 17
cytosol. Importin-β is the carrier molecule that transports the cargo through the NPC 
while importin-α acts as an adapter protein. Once inside the nucleus, Ran – GTP binds 
importin-β which causes it to dissociate from importin-α. Importin-α then dissociates 
from the cargo molecule and is ready to be recycled to the cytoplasm through its 
nuclear export factor CAS which is also bound to Ran – GTP. Once the importin-
α/CAS/Ran – GTP complex reaches the cytoplasm, RanGAP, which is found only 
outside the nucleus, catalyzes the hydrolysis of GTP to GDP. This causes the release 
of importin-α for another cycle of transport. Ran – GDP is then transported back into 
the nucleus by NTF2 (Nuclear Transport Factor-2) where it can be activated again by 
the RanGEF, RCC1 (Regulator of Chromosome Condensation), and thus the cycle is 
perpetuated. This spatial separation of the RanGEF and RanGAP into the nucleus and 
cytoplasm, respectively, are important for the proper regulation of Ran and controls 
the directionality of transport through the NPC. 
 As mentioned earlier, Ran is also implicated in mitotic control. Until fairly 
recently, the evidence was fairly controversial. The question arose as to whether Ran 
is involved directly in mitotic control as well as if its involvement is a distinct and 
separate function from nuclear transport. There is now proof that Ran functions in 
mitosis after the break-up of the nuclear envelope. As reviewed by Ciciarello et. al. 
(40), activating mutants of Ran induced the assembly of microtubule asters and 
spindles in M phase arrested Xenopus oocyte extracts, whereas a dominant negative 
mutant was inhibitory. Furthermore, it has been shown that activated Ran releases 
TPX2, a protein that is known to regulate spindle pole formation through a kinesin, 
from importin-α containing complexes. Similarly, activated Ran has been shown to 
stimulate the release of another spindle pole organizer, NuMA, from an importin-α/β 
complex. A model has been developed in which, before mitosis, there is an 
accumulation of SAFs (Spindle Activating Factors) bound to either the importin α/β 
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complex or importin-β alone in the nucleus. After the nuclear envelope breaks down, 
RCC1 associates with chromatin and causes a localized concentration of activated Ran 
around the chromatin that diffuses away causing a gradient. Thus inhibition of SAFs is 
relieved in a gradient dependent manner where the greatest activity of SAFs is around 
the chromatin. There is now evidence that Ran is also involved in centrosomal 
duplication, stabilization of microtubules, promotion of microtubule plus end directed 
movement, chromosomal “search and capture” by microtubules, and exiting of M 
phase into G1.  
 
Rho GTPases 
 
 The Rho sub-family of Ras-like G proteins consists of at least 26 different 
members (41) of which Rho (Ras homologous), Rac (Ras-related C3 botulinum toxin 
substrate), and Cdc42 (Cell Division Cycle mutant 42) are the best characterized. 
Similar to their Ras-like brethren, they cycle between a GTP (active) and GDP 
(inactive) state that is highly regulated by GEF and GAP proteins. In addition, much 
like the Rabs, they can be sequestered in the cytoplasm and shuttled between 
membranes by RhoGDI. Rho members are involved in a variety of essential cellular 
processes such as cytoskeletal organization, cellular trafficking, cellular polarity, 
proliferation, and apoptosis. In fact, Rho, Rac, and Cdc42 are absolutely essential for 
cell cycle progression through the G1 to S phase transition in mammalian cells (42). 
 Rho family G proteins interact with over 60 downstream effectors, the largest 
number of effectors for any family of G proteins, indicative of their many cellular 
roles (43). To complicate matters, they also share many of the same targets, especially 
Cdc42 and Rac which are about 68% identical based on primary sequence alignments. 
In addition, there are over 60 GEF proteins and over 70 GAP proteins in the human 
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genome regulating Rho family members (44). Many GEF and GAP proteins regulate 
multiple Rho family members while some even contain domains which regulate other 
small G protein family members (44).    
The first discovered function for Rho family members was their involvement in 
cell morphological changes related to the cytoskeleton. It was originally observed, 
through microinjection experiments, that Rho caused stress fiber formation in a 
number of cell lines (45). Later it was confirmed that endogenous Rho caused stress 
fiber formation as well as focal adhesion complex formation in response to LPA 
(lysophosphatidic acid) (46). Rac as well as Cdc42 were soon to follow as it was 
shown that Rac caused lamellipodia (membrane ruffles) formation as well as focal 
adhesion complex formation that were distinct from Rho, while Cdc42 caused 
filopodia (actin spikes at the leading edge) formation in Swiss 3T3 cells (47).  
Additionally, Cdc42 was observed to activate Rac which then activated Rho in a 
sequential manner in NIH 3T3 cells.  
 Soon after the discovery of the role of Rho family proteins in cytoskeletal 
rearrangements, another major function in mitogenic signaling and cellular 
transformation was found. Constitutively active Rac and Rho were found to cause 
transformation in fibroblasts (48-50). Similarly, a fast-cycling mutant of Cdc42 
(F28L), which no longer required a GEF to become activated, showed hallmarks of 
cellular transformation when stably expressed in NIH3T3 cells (51). Indeed, it was 
shown that the ability of Cdc42 to cycle at an accelerated rate between its GDP- and 
GTP-bound states was necessary for inducing cellular transformation, whereas GTP 
hydrolysis defective forms of Cdc42 were toxic to cells. Finally, it was shown that 
Rho, Rac, and Cdc42 were each necessary for Ras induced transformation, clearly 
defining their importance in cellular processes (50,52-54).  
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 In the intervening years, much has been learned about Rho family member 
cellular pathways. For instance, it has been shown that Rac1 and Cdc42 can regulate 
the stress activated p38 and JNK MAPK pathways directly which leads to the 
expression of genes in the nucleus (55,56). Activation of these pathways by both Rac 
and Cdc42 are mediated by at least two serine/threonine kinases, PAK (p21 activated 
kinase), and MLK3 (Mixed lineage kinase) which are substrates for both G proteins 
(57,58). In addition, PAK can phosphorylate MEK1 which then activates ERK in a 
way that seems to act synergistically with Raf-1 in ERK activation (59).  
Recently, indirect routes for Cdc42-mediated regulation of MAPK signaling have 
been shown to be just as important. These routes involve a non-traditional Cdc42 
effector named Cool (Cloned out of library) or PIX (for p21-interacting exchange 
factor) which will be referred to hereafter as Cool. The Cool family of proteins were 
first discovered through their association with PAK (60,61). Later studies found Cool 
proteins also associated with c-Cbl (Casitas B lymphoma), an E3-ubiquitin ligase 
necessary for the ubiquitination and subsequent degradation of receptor tyrosine 
kinases, including EGFR (62-64).  Due to the presence of the tandem DH/PH motif 
commonly found in RhoGEF proteins, it was assumed that they functioned as GEFs 
for Rho family members. Interestingly, unlike most GEFs, it was discovered that 
Cool-1 bound preferentially to activated Cdc42 instead of the inactivated form (65). 
This finding was all the more intriguing due to previous data showing that by 
inhibiting the ability of c-Cbl to catalyze the ubiquitination of EGFRs, there was 
significantly enhanced EGF-dependant activation of MAPK activity (63,64). This lead 
to the discovery that cells transfected with fast-cycling Cdc42(F28L) had a greater 
number of EGF receptors at the cell surface and exhibited sustained EGF-coupled 
signaling activities (65). Wu and his colleagues went on to show that loss of the 
interaction between Cdc42 (F28L) and Cool-1, or between Cool-1 and c-Cbl, was 
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sufficient to abolish Cdc42 (F28L) mediated cellular transformation. A model was 
proposed whereby activated Cdc42 binds Cool-1 which itself is bound to c-Cbl and 
sequesters c-Cbl away from the EGFR. As a result, EGFR is not degraded but instead 
recycled back to the plasma membrane where it continues to signal to the nucleus. 
Rho family members and their effectors are involved in a multitude of signaling 
pathways which often intersect and synergise with other pathways to perform an array 
of functions. The mechanisms for some of these functions have yet to be determined 
but there is no question as to the Rho family proteins importance in the cell. 
 
Structural considerations  
 The structure of Ras was the second small G protein structure to be solved 
after the bacterial elongation factor EF-Tu (66,67). The GTP-binding domain was 
found to be nearly identical between the two structures, encompassing a domain 
containing 6 β-strands and 5 α-helices. It is now known that this is a common fold for 
all G proteins including the heterotrimeric G proteins. Ras is considered to be the 
minimum structural fold for G proteins and as such, is the standard by which all other 
small G proteins are compared.  
With the advent of molecular cloning techniques during the 1980s, increasing 
numbers of G proteins were discovered and more sequences were available for 
comparisons. It was appreciated early on that there were regions in the heterotrimeric 
Gα subunits that were highly conserved and important for binding the guanine-
nucleotide. After the previously mentioned structures of EF-Tu and Ras were 
published, it was noted that there were 5 regions of conservation named G1-G5 across 
all G protein families that were critical for GTP-binding and hydrolytic activity (68). 
These regions include the GXXXXGK(S/T) or P-loop, DXXG which binds to the γ-
phospahte as well as the Mg2+ ion, N/TKXD which binds the guanine ring, the SAK 
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motif which confers specificity, and a region encompassing Switch I (see below) 
which includes Thr35 that coordinates the Mg2+ (69,70).  
As seen in the crystal structures for Ras, the differences between signaling-
active and signaling-inactive forms of G proteins reflect structural rearrangements in 
two loop regions encompassing amino-acids 30-38 and 60-76 named Switch I and 
Switch II respectively (71). It was revealed both biochemically and structurally that 
these regions are the sites of interaction with downstream targets. Due to the amount 
of sequence homology in the switch regions across all G proteins and the availability 
of various structures, it is widely accepted that this rearrangement is likely true for all 
small GTPases. In fact, this rearrangement has also been shown to be true for the 
heterotrimeric G proteins as well (72). 
Turning G proteins on at the proper time is essential for the proper functioning 
of the cell. Direct activation is achieved by GEFs in the case of small G proteins, 
whereas heptihelical receptors serve an analogous role for the large G proteins. 
Structurally, GEFs do not share significant homology, however they do share a 
common mechanism of action. In general, GEFs bind the switch regions and perturb 
the Mg2+ as well as the phosphate-binding site (44). Often, negatively charged 
residues found within Switch II are brought into close proximity to the β-phosphate of 
GDP while an alanine, either from the GEF or found within the DXXG motif on 
Switch II, is used to clear the Mg2+-binding site. The dissociation of Mg2+, coupled 
with phosphate destabilization, decreases the affinity between the G protein and GDP 
by several orders of magnitude allowing for GDP to dissociate. Intracellular GTP, 
which is at a 10 fold higher concentration than GDP, is then free to bind and thus 
activate the G protein. 
Similarly, GAPs across the different G protein families share little structural or 
sequence homology but often employ similar mechanisms to catalyze the GTPase 
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activity. Nearly all G proteins exhibit an intrinsic ability to hydrolyze GTP to GDP 
and Pi, albeit at a rate that is too slow to for the precise timing of signals required by 
the cell. In general GAPs work by helping to orient a nucleophilic water molecule, 
usually via a glutamine residue located within the Switch II region of the G protein, 
and by stabilizing the negative charge that builds up on the γ-phosphate with the help 
of an arginine residue, usually referred to as an “arginine finger”, either supplied by 
the GAP in the case of small G proteins, or by the large helical domain unique to Gα 
subunits (44,70). The rates of GTP hydrolysis vary depending on the G protein, 
however heterotrimeric α-subunits typically have higher rates than Ras-like small G 
proteins due to the presence of the arginine residue already found in their helical 
domain.  Additionally, there is evidence that stabilization of the switch regions by the 
GAP, even in the absence of the “arginine finger”, may be an important part of the 
catalytic process (73). 
 
Rho family structure 
The first X-ray crystal structure of a Rho family member G protein, Rac1, was 
solved in 1997 (74).  Other Rho family members Rho and Cdc42 were soon to follow. 
Rho family members are distinguished from other small G proteins by the presence of 
a helical insert comprising 13 amino acid residues (i.e. 123 – 135 in the case of Rac 
and Cdc42). The function of this insert is largely unknown. However, it has been 
shown that replacement of this region with the corresponding Ras sequence inhibits 
the ability of Rho-family proteins to transform cells (75,76). 
   
Overview of thesis research: 
Activated structures of Cdc42 bound to effector and regulatory molecules have 
been solved using both NMR and x-ray crystallography. In addition, the signaling-
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inactive structures (GDP-bound) of Cdc42 have been solved both in the presence and 
absence of RhoGDI (Guanine-nucleotide Dissociation Inhibitor) (77,78). These 
structures have provided many insights into the mechanisms for Cdc42 activation, 
GTP hydrolysis, as well as effector protein interaction.  
 Upon comparison of signaling-active Cdc42 in complex with effector proteins 
versus the signaling-inactive structures of Cdc42 (G12V) (pdb id. 1A4R) as well as 
Cdc42-GDP (pdb id. 1ANO) it seems evident that Cdc42 shares a similar activation 
mechanism with Ras.  As mentioned earlier, activation of Ras leads to the re-
orientation of two loops located in the effector-binding region named Switch I and 
Switch II, residues 30-40 and 60-76 respectively (71). These regions serve as the 
binding interface between Ras and its effectors and as such, are sometimes referred to 
as effector loops. Effector proteins for Cdc42 containing CRIB domains bind in a 
similar manner. They form an intermolecular β-sheet with strand β2 from Cdc42, 
which is located just after Switch I. However, unlike Ras, Switch II in Cdc42 appears 
to be much more rigid and does not rearrange between the inactive (GDP) and active 
(GTP) structures. Switch I however shows a relatively large conformational transition 
in the activated effector-bound structures when compared to the inactive structures. 
This implies that the activation of Cdc42 is accompanied by the rearrangement of 
Switch I into an orientation that can now be recognized by effector proteins, similar to 
what has been shown for Ras. However, there is no structure yet available for an 
activated Cdc42 – GTP-analog complex to compare with the effector-bound 
structures. With this in mind, the focus of my thesis has been to try and understand the 
exact mechanism of Cdc42 activation. 
 To this end, I provide evidence in the following two chapters that, contrary to 
what was expected, signaling-active Cdc42 undergoes virtually no structural 
rearrangement upon binding a GTP analog when compared to Cdc42 – GDP. Instead, 
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coupling of an effector protein is necessary for Cdc42 to achieve a fully activated 
structure. Furthermore, in the final chapter, I show that the constitutively activated 
Cdc42 (Q61L) mutant bound to the non-hydrolyzable guanine-nucleotide analog 
GMP-PCP, does indeed show a structural rearrangement consistent with the effector-
bound structures for Cdc42. Interestingly, direct comparisons between GTP- and 
GMP-PCP-bound Cdc42 (Q61L) by 31P-NMR revealed that both nucleotides confer 
similar properties on the protein. These results imply that the Q61L point mutant alters 
the thermodynamics of Cdc42 so as to favor the activated structure. Additionally, 
these results are consistent with previously derived Kd values for both wild-type and 
Q61L mutant forms of Cdc42 whereby the Q61L isoform has been shown to have an 
order of magnitude higher affinity for effector proteins than wild-type (79,80).       
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Chapter 2 
 
EFFECTOR PROTEINS EXERT AN IMPORTANT INFLUENCE ON THE 
SIGNALING-ACTIVE STATE OF THE SMALL GTPASE CDC42 
 
  
Abstract 
 GTP-binding (G) proteins regulate the flow of information in cellular signaling 
pathways by alternating between a GTP-bound “active” state, and a GDP-bound 
“inactive” state.  Cdc42, a member of the Rho family of Ras-related small G-proteins, 
plays key roles in the regulation of cell shape, motility, and growth.  Here we describe 
the high-resolution X-ray crystal structure for Cdc42 bound to the GTP-analog GMP-
PCP (i.e. the presumed signaling-active state) and show that it is virtually identical to 
the structures for the signaling-inactive, GDP-bound form of the protein, contrary to 
what has been reported for Ras and other G-proteins.  Especially surprising was that the 
GMP-PCP- and GDP-bound forms of Cdc42 did not show detectable differences in 
their Switch I and Switch II loops.  Fluorescence studies using a Cdc42 mutant in which 
a tryptophan residue was introduced at position 32 of Switch I also showed that there 
was little difference in the Switch I conformation between the GDP- and GMP-PCP 
bound states (i.e. <10%), which again differed from Ras where much larger changes in 
Trp32 fluorescence were observed when comparing these two nucleotide-bound states 
(>30%).  However, the binding of an effector protein induced significant changes in the 
Trp32 emission specifically from GMP-PCP-bound Cdc42, as well as in the phosphate  
_________________________ 
* Phillips, M. J., Calero, G., Chan, B., Ramachandran, S., and Cerione, R. A. (2008) J. Biol. 
Chem. 283, 14153-14164  
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resonances for GTP-analogs bound to this G-protein as indicated in NMR studies.  An  
examination of the available structures for Cdc42 complexed to different effector 
proteins, versus the X-ray crystal structure for GMP-PCP-bound Cdc42, provides a 
possible explanation for how effectors can distinguish between the GTP- and GDP-
bound forms of this G-protein and ensure that the necessary conformational changes for 
signal propagation occur. 
  
Introduction 
 Cdc42 is a member of the Rho family of Ras-related small G-proteins and is an 
essential protein found in all eukaryotic organisms including yeast, flies, and mammals 
(1-3).  Like Ras, the founding member of the small G-protein family (4), Cdc42 
undergoes a GTP-binding/GTP-hydrolytic cycle that enables it to act as a molecular 
switch in cells.  It is activated to undergo GDP-GTP exchange by members of the Dbl-
family of guanine nucleotide exchange factors (GEFs) (5-7).  GTP-bound Cdc42 can 
bind and/or activate over 20 downstream effector proteins that are responsible for 
mediating a diversity of cellular functions, including actin cytoskeletal remodeling, cell 
polarity, intracellular trafficking, EGF receptor degradation, and cell cycle progression 
(1-3,8).  These different signals are terminated when Cdc42 is deactivated through its 
ability to hydrolyze GTP, a reaction that is catalyzed by GTPase-activating proteins 
(GAPs) (9).   
Structural studies of a number of GTP-binding proteins, beginning with the bacterial 
elongation factor, Ef-Tu, and including H-Ras and the α subunits of various members of 
the family of large G-proteins, have shown that a conserved architecture exists for GTP-
binding and hydrolytic activity, comprising five α-helices and six β-strands (10-14).  
Moreover, comparisons of the X-ray crystal structures for many of these proteins bound 
to GDP and GTP-analogs highlighted two regions called Switch I and Switch II that 
change their conformation upon GDP-GTP exchange.  In the case of H-Ras and related 
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small G-proteins, Switch I encompasses residues 30-38 within the α1-β2 loop while 
Switch II is made up of residues 60-76 within β3-α2 (12,15).  It has been commonly 
assumed that changes in these Switch regions represent the underlying basis for GTP-
dependent signal propagation and indeed Switch I has been shown to be a principle site 
used by Ras and related small G-proteins including Cdc42 to engage their downstream 
effectors. 
Given the shared architecture between Ras, Cdc42 and other Rho-family small G-
proteins, there was every reason to expect that Cdc42 would exhibit the same types of 
GTP-dependent changes in Switch I and II, as originally described for H-Ras.  
However, surprisingly, we found that this was not the case.  The high-resolution X-ray 
crystal structure for Cdc42 complexed to the non-hydrolyzable GTP-analog GMP-PCP 
was virtually identical to that for Cdc42 bound to GDP, despite the fact that only GMP-
PCP-bound Cdc42 and not its GDP-bound counterpart is able to productively engage 
effector proteins.  Likewise, we found that Cdc42 molecules containing a tryptophan 
residue inserted into position 32 of Switch I, in place of the normal tyrosine residue, 
showed little or no change in their tryptophan fluorescence, when comparing the GMP-
PCP- and GDP-bound forms of the protein.  These results again differed from those 
obtained with the corresponding Switch I mutant of H-Ras, which showed significant 
changes in the fluorescence of the Switch I tryptophan residue when comparing the 
GDP- and GMP-PCP-bound states.   
Thus taken together, these findings raised the question as to how effector proteins 
are able to selectively recognize the GTP-analog-bound form of Cdc42, and whether 
effectors might be capable of inducing and/or stabilizing specific conformational 
transitions within a Cdc42 species that appears to start-off predominantly in a signaling-
inactive conformation.  Here we show that despite the GDP- and GMP-PCP-bound 
forms of Cdc42 sharing a similar Switch I conformational state, the tryptophan 
fluorescence of the GMP-PCP-bound Cdc42(Y32W) mutant undergoes a specific and 
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significant change upon the binding of an effector protein.  NMR experiments also 
showed that effector proteins were able to specifically promote conformational changes 
within Cdc42 molecules bound to GTP-analogs.  When this structure-function 
information is considered together with the structures for Cdc42 complexed to effectors 
that either use the conventional Cdc42/Rac-interactive-binding (CRIB) domain, such as 
is the case for Pak (for p21-activated kinase) (16), or a non-conventional Cdc42/Rac-
binding domain, as occurs with Par6 (for Partitioning-defective protein-6) (17), it 
becomes apparent how effector proteins help to ensure that Cdc42 undergoes the 
necessary conformational changes for signal propagation.  
Overall, our findings support the idea that there is a spectrum of possibilities 
regarding the conformational states that G-proteins can assume following the exchange 
of GDP for GTP (or GTP-analogs), i.e. what is commonly referred to as the G-protein 
activation event.  One end of the spectrum represents cases like Cdc42 where, in the 
absence of an effector protein, the majority of the population of the GTP- (or GTP-
analog-) bound G-protein exists in conformational states that are minimally changed 
from those for the GDP-bound form of the protein.  Thus, Cdc42 relies heavily upon 
effector proteins to induce the correct conformational changes to enable signal 
propagation to occur. At the other end of the spectrum are the Gα subunits of 
heterotrimeric (large) G-proteins, and small G-proteins like H-Ras where, upon GDP-
GTP exchange, the majority of the G-protein population assumes conformational states 
that clearly differ from the GDP-bound protein and more closely approximate the 
signaling-active, conformational states that are formed upon the binding of effectors.   
 
EXPERIMENTAL PROCEDURES 
 
 Protein purification- E. coli cells expressing pET15b-his-Cdc42, pGEX-KG-
Cdc42(Y32W, W97H), pGEX-KG-PBD (W98F), and pGEX-KG-PBD were grown at 
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37˚C until an O.D. of 0.8.  Induction was initiated by the addition of IPTG (1 mM) and 
the cells were allowed to grow for another 3 hours.  Cells were pelleted at 6000 x g for 
10 minutes and frozen at  -80˚C.  Cell pellets were homogenized in HMA (20 mM 
Hepes, pH 8.0, 5 mM MgCl2, 1 mM NaN3) buffer and lysed by sonication.  Cell debris 
was centrifuged at 20,000 rpm for 30 minutes and the supernatant was saved.  
Supernatants containing 6-histidine (His)-tagged Cdc42 were incubated briefly with 
Chelating-Sepharose beads (Amersham) charged with Ni2+ and equilibrated with HMA.  
Beads were washed with HMA plus 20 mM imidazole before elution with HMA plus 
200 mM imidazole.  GST-tagged proteins were incubated with glutathione-beads 
(Amersham) equilibrated with HMA for 30 minutes at 4˚C.  Beads were washed with 
HMA containing 500 mM NaCl and again with HMA.  Protein was eluted with 10 mM 
glutathione in HMA. 
 The His-tagged proteins were incubated with thrombin (Haematological 
Technologies Inc.) at 4˚C for 3-4 hours.  Clipped proteins were further purified by 
chromatography on a HiTrap Q column (Amersham) and protein fractions were pooled.  
 Nucleotide loading- Mutant and wild-type Cdc42 protein concentrations were 
measured using Bradford reagent (Pierce).  Non-hydrolyzable nucleotide analogs were 
added to an ~5-fold excess relative to the protein concentration.  Ammonium sulfate 
was added to a final concentration of 200 mM along with 100 units of alkaline 
phosphatase-bound acrylic beads (Sigma # P0927).  After a 4 hour incubation at 4˚C, 
the beads were washed with HMA and the flow-through was collected.  The buffer was 
exchanged on a PD-10 column (Amersham) equilibrated with HMA.  Nucleotide 
content was confirmed by HPLC analysis, using a previously published protocol (18). 
 GST-Cdc42 pull-down assays-  Equal amounts of glutathione-beads (Amersham) 
were saturated with GST-Cdc42 bound to GMP-PCP, GMP-PNP, GTPγS, or GDP.  
After incubation for 1 hour at 4˚C, the beads were washed 3x with HMA and an 
equivalent amount of the limit Cdc42/Rac-binding domain from Pak3 (PBD) was added 
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to a 10-fold molar excess of Cdc42.  Beads were washed 3 x with HMA after a 3 hour 
incubation at 4˚C.  Equal amounts of protein from each assay were boiled and loaded on 
a 4%-20% gradient gel (Invitrogen). 
 X-Ray crystallography-  Cdc42-GMP-PCP (80 mg/ml) crystals were grown in 12% 
PEG 6K, 100 mM ammonium sulfate, 100 mM Na acetate and 50 mM MES, pH 6.0, at 
18˚C.  Data was collected at the Cornell MacCHESS beamline A1 using an ADSC 
Quantum-210 CCD Detector.  Data processing was performed using Mosfilm and initial 
phases were solved by molecular replacement using MolRep from the CCP4 suite (19). 
The model structure used to find the initial phases was Cdc42-GDP (PDB ID 1AN0) 
without nucleotide. Structure refinement was completed using CNS (20) and validated 
with Procheck (21).  
 31P-NMR- Samples were prepared by dissolving Cdc42 (1 mM) pre-exchanged with 
GMP-PNP or GMP-PCP, either with or without the PBD (1 mM), in HMA containing 
10% D2O.  31P spectra were obtained at 5˚C on a Varian INOVA spectrometer operating 
at 202.37 MHz using a 5 mm Varian DBG probehead. 1H broadband decoupling was 
applied throughout the acquisition.  A relaxation delay of 8 seconds was used between 
scans, with 3000 - 4000 scans summed prior to analysis.  Data was zero-filled to 128k 
points and an exponential multiplication (5 - 10 Hz) was performed prior to Fourier 
Transform.  Spectra were referenced externally to 85% phosphoric acid (0 ppm). 
  Fluorescence spectroscopy- All experiments were performed on a Varian Cary 
Eclipse fluorimeter.  Excitation and emission slit widths were ±5 nm and ±10 nm, 
respectively.  Cdc42 and H-Ras emission-scan experiments were performed in HMA at 
30˚C, using an excitation wavelength of 295 nm in HMA.  Excitation and emission 
wavelengths for the binding assays of Cdc42(Y32W, W97H) with PBD(W98F) were 
295 nm and 353 nm, respectively. 
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RESULTS 
 
The X-ray crystal structure for GMP-PCP-bound Cdc42- The original X-ray crystal 
structures for the signaling-active (GTP-bound) form of H-Ras were obtained using the 
non-hydrolyzable GTP-analogs GMP-PNP and GMP-PCP (11,12), because GTP as 
well as GTPγS are hydrolyzed during the crystallization procedure.  As is the case for 
Ras, these two non-hydrolyzable GTP-analogs enable Cdc42 to interact with its 
downstream effector proteins.  An example is presented in Figure 2.1 that shows the 
selective ability of GST-Cdc42, when bound to different GTP-analogs, to pull-down the 
limit Cdc42/Rac-binding domain from Pak3 (i.e. the PBD), whereas the GDP-bound 
form of GST-Cdc42 was unable to bind to the effector.  We therefore used the Cdc42-
GMP-PCP complex for high-resolution structural analysis of the signaling-active form 
of this G-protein. 
Figure 2.2A shows the ribbon diagram for the X-ray crystal structure for GMP-PCP-
bound Cdc42 solved to 2.4 Å resolution (see Table 1 below for statistics on data 
collection and refinement).  The structure conforms to an α/β fold comprised of six β-
strands, six α-helices and one 3/10 helix, and in general displays an architecture that is 
characteristic of other small G-proteins.  Stabilization of the GMP-PCP molecule inside 
the nucleotide-binding pocket is achieved through hydrogen bonds between the guanine 
ring and surrounding residues, π-π stacking interactions with Phe28, and hydrogen 
bonds with the phosphate oxygen atoms.  Figure 2.2B shows a representative electron 
density for a portion of the GMP-PCP-binding site. 
There are two molecules of GMP-PCP-bound Cdc42 within the asymmetric unit. 
Crystal contacts involving Switch I from chain A help to stabilize the loop, specifically, 
at residues Tyr32 and Phe37.  A cleft is formed by Met1, Pro50, and Met45 in a 
symmetry-related molecule which provides a hydrophobic interface for the phenyl 
group of Tyr32 in Switch I.  The formation of a hydrogen bond between Tyr32 and  
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FIGURE 2.1.  Interaction between signaling-active forms of Cdc42 and the p21-
binding domain of Pak3.  Glutathione-beads were saturated with GST-Cdc42 (700 μg) 
bound to GDP, GMP-PCP, GMP-PNP, or GTPγS.  Washed beads were incubated with 
a 10-fold molar excess of Pak3-PBD (p21-binding domain) for 3 hours and washed.  
Lane 1 shows signaling inactive Cdc42-GDP is ineffective at binding target.  Lanes 2-4 
show signaling-active Cdc42 is able to interact with PBD, which is detected as a 
doublet of 8 kDa – 10 kDa. PBD appears as a doublet most likely due to non-specific 
proteolytic cleavage from the bacterial host’s proteosome.     
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TABLE 1 
  
a Rsym = Σhkl Σi[Ii(hkl) - <I(hkl)>]/ΣhklΣi(hkl)
b Rfree and Rf = Σ|Fobs – Fcalc|/ ΣFobs 
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Ramachandran 
Refinement Statistics 
95.5 (91.4) Completeness %, (highest resolution) 
31 – 2.4 Refinement resolution range (Å) 
991 (5%) Number of reflections in test set 
18448 (95%) Number of reflections in working set 
1.4 rms deviation from ideal bond angle (¢ª) 
0.010 rms deviation from ideal bondlength (Å) 
12.3 % Allowed regions 
87.3 % Most favored regions 
23 Rf b (%) 
26 Rfreeb (%) 
6.8 (39) Rsyma (highest resolution)(%) 
6.8 (2) I/óI 
4.1 (2.8) Average Redundancy (highest resolution) 
2.4 Resolution (Å) 
98.5, 98.5, 102.4 Unit Cell (Å) 
P41212 Space Group  
Data Collection and refinement statistics for Cdc42-GMPPCP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
FIGURE 2.2 A-C  X-ray crystal structure of GMP-PCP bound Cdc42 at 2.4 Å.  A, 
Overall fold of GMP-PCP-bound Cdc42 is a classic G domain encompassing six β-
sheets and five α-helices with a short two-helical insertion after the β-strand 5 known as 
the Rho-insert region.  The α-helix 4 is a short 3-10 helix.  Switch I and II are colored in 
red encompassing residues 30-37 and 60-70 respectively.  P-loop residues, which are 
important for binding the phosphates, are colored green.  B, Electron density around the 
GMP-PCP is contoured at 1.5σ  (green) and 4σ (blue) from a 2fo-fc map.  Clear density 
is present for the γ-phosphate even at 4σ.  C, Structural alignment of the signaling-
active Cdc42-GMP-PCP complex (grey) with the signaling-inactive Cdc42 (G12V)-
GDP (blue).  Switch regions and the P-loop are colored red and green, respectively.  
There is an overall r.m.s.d. of 0.75 Å for all Cα atoms between the two structures.  D 
and E, Close-up views of the Mg2+ coordination between the Cdc42 (G12V)-GDP and 
Cdc42-GMP-PCP structures, respectively.  Phosphates and magnesium are shown in 
orange, whereas water and nitrogen molecules are colored blue. Threonine 35 does not 
coordinate to the γ-phosphate in the Cdc42-GMP-PCP structure as it does in other 
signaling active structures.  It is replaced by a water molecule in the Cdc42 structures, 
while all other contacts are conserved.  Figures 2.2 and 2.3 were created with Pymol 
(50). 
 
 
 
 43
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 44
  
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 45
  
 
 
C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 46
  
 
 
 
 
D.  
 
 
 
 
 
 
 
 
 
E.  
 
 
 
 
 
 
 
 
 
 
 47
Thr35 from chain A helps to prevent Thr35 from coordinating the Mg2+ (also see 
below), while Phe37 is stabilized by π-π interactions with Tyr64 from a symmetry-
related molecule. The individual temperature factors for residues within Switch I are 
higher than those found in adjacent areas of the protein where secondary structure 
stabilizes the residues.  Moreover, the temperature factors for Switch I residues in chain 
B are higher than those for the corresponding residues in chain A.  This is probably due 
to the fact that Phe37 in chain B does not undergo π-π interactions with a symmetry-
related molecule.  
 
Comparisons of the structures for the GMP-PCP- and GDP-bound forms of Cdc42- 
Based on the X-ray crystallographic studies of H-Ras (11,12) and various Gα subunits 
of the family of heterotrimeric or large G-proteins (13,14), as well as the corresponding 
structures for the elongation factor Ef-Tu (10), it has been suggested that there are two 
conserved regions designated as Switch I and Switch II that undergo conformational 
changes as an outcome of GDP-GTP exchange (often referred to as the G-protein-
activation event).  Thus, it has been generally assumed that changes occurring in Switch 
I and Switch II underlie the molecular switch function of both small aqnd large G-
proteins, enabling them to selectively engage their downstream signaling effector 
proteins.  However, the X-ray crystal structure for the GMP-PCP-bound form of Cdc42 
was immediately intriguing because when it was compared to signaling-inactive forms 
of Cdc42, these structural differences were not evident. The overall topology of the 
Cdc42-GMP-PCP complex, and its Switch I and II conformations in particular, were 
virtually identical to both the X-ray crystal structure that we had earlier solved for the 
GDP-bound form of Cdc42 (PDB ID 1ANO), as well as the reported structure for a 
signaling-inactive Cdc42(G12V)-GDP complex (22).  Figure 2.2C compares the Cdc42-
GMP-PCP and Cdc42(G12V)-GDP complexes.  A structural alignment of all the Cα 
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atoms between these two complexes yielded an r.m.s deviation of approximately 0.75 
Å. 
The coordination of the Mg2+ ion is also virtually identical in the structures for the 
signaling-inactive GDP-bound form of Cdc42 versus the Cdc42-GMP-PCP complex 
(Figures 2.2D and 2.2E, respectively).  It is interesting that in GMP-PCP-bound Cdc42, 
Thr35 does not participate in Mg2+ coordination, given that it has been suggested to be 
critical for the structural change imparted by GTP-analogs within the Switch I loop of 
H-Ras (23,24).  Specifically, Thr35 appears to interact with the γ-phosphate of GTP in 
Ras with this interaction being lost upon GTP hydrolysis and thereby possibly 
accounting for the observed change in the orientation of Switch I.  In the structure for 
the Cdc42-GMP-PCP complex, Thr35 is not in position to coordinate the Mg2+ ion; 
however, a water molecule is visible and substitutes for the hydroxyl group of the 
threonine residue.  The same is true for the structure for the GDP-bound form of Cdc42, 
as well as for the Cdc42(G12V)-GDP complex (22).   
The Cdc42-GMP-PCP complex crystallized in the same space group and unit cell 
dimensions as the Cdc42(G12V)-GDP complex.  As a result, both the GDP- and GMP-
PCP-bound Cdc42 structures share similar crystal contacts that help to stabilize Switch 
I.  Many of these crystal contacts are absent in the second Cdc42-GMP-PCP molecule 
that is present within the asymmetric unit for the GTP-analog-bound form of the G-
protein.  While the electron density for Switch I from the second Cdc42 molecule shares 
a similar backbone conformation with Switch I from the first Cdc42 molecule within 
the asymmetric unit, it possesses elevated B factors.  This leads us to suspect that 
Switch I is probably highly mobile in both the GDP- and GMP-PCP-bound forms of 
Cdc42, an idea supported by NMR findings (25,26).  Thus, crystal contacts have 
probably enabled us to view one conformational state from possibly a number of states 
that may be shared by these two nucleotide-bound forms of Cdc42.  
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Fluorescence studies of GDP- versus GMP-PCP-bound Cdc42- We have taken 
advantage of the sensitivity of fluorescence spectroscopy to further examine the Switch 
I conformations for the GDP- and GMP-PCP-bound forms of Cdc42.  The basic 
strategy was to first eliminate any background tryptophan fluorescence from Cdc42 by 
changing the tryptophan at position 97 to a histidine, and then to introduce a tryptophan 
residue at position 32 of Switch I, in place of the usual tyrosine residue.  The 
expectation was that the Trp32 residue would serve as a conformational probe for 
Switch I in Cdc42.  This approach has been successfully used with H-Ras to detect 
conformational changes within Switch I upon GDP-GTP exchange (although in the case 
of H-Ras there are no tryptophan residues in the wild-type protein and so only the single 
substitution at position 32 was necessary) (27).  Indeed, Figure 2.3A shows that there is 
a significant difference in the intrinsic fluorescence measured for the H-Ras(Y32W) 
mutant when comparing its GDP- and GMP-PCP-bound states, such that the binding of 
the GTP-analog results in an ~30% quenching in the Trp32 fluorescence.  On the other 
hand, the differences in the intrinsic fluorescence for the corresponding forms of the 
Cdc42(Y32W, W97H) mutant were much more subtle with GMP-PCP-bound Cdc42 
showing at most a 5-10% decrease in Trp97 fluorescence compared to its signaling-
inactive, GDP-bound counterpart (Figure 2.3B).  Thus, these findings corroborated the 
results from X-ray crystal studies that showed the differences between the GDP- and 
GTP-analog-bound forms of Ras were much more pronounced than the differences for 
the corresponding forms of Cdc42.  Nonetheless, effector proteins are still able to 
distinguish between the GDP- and GMP-PCP-bound forms of Cdc42, as we observed a 
significant change in the fluorescence of the GMP-PCP-bound Cdc42(Y32W, W97H)  
protein (Figure 2.4A), but not in the GDP-bound form of the protein (Figure 2.4B), 
upon the addition of a recombinant form of the PBD in which its sole tryptophan 
residue was changed to a phenylalanine [PBD(W98F)]. Successive additions of 
PBD(W98F) resulted in a dose-dependent quenching of the fluorescence from GMP- 
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FIGURE 2.3 A-B  Fuorescent spectra of the signaling-active and inactive forms of 
Ras (Y32W) and Cdc42 (Y32W, W97H).  A, H-Ras(Y32W) (1 μM) bound to GDP 
(top) or GMP-PCP (bottom) was scanned at an excitation wavelength of 295 nm.  A 
decrease in quantum yield of nearly 30% is observed upon binding of GMP-PCP.  B, 
The same experiments performed with the Cdc42(Y32W, W97H) mutant show that 
only a minor difference in quantum yield is observed between the GDP- and GMP-
PCP-bound forms of the protein. 
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FIGURE 2.4 A-C  Effector-induced changes in the Switch I conformation of GMP-
PCP-bound Cdc42.  A, The addition of the limit Cdc42/Rac-binding domain of Pak3 
(PBD) (1 μM) to GMP-PCP-bound Cdc42(Y32W, W97H) (1 μM) causes a quenching 
of Trp32 fluorescence.  B, The addition of the PBD to GDP-bound Cdc42(Y32W, 
W97H) has no effect on Trp32 fluorescence. Titration (0.2-4 μM) of GMP-PCP-bound 
Cdc42(Y32W, W97H) with increasing amounts of PAK3-PBD (W98F).  C, Addition of 
PBD (W98F) decreases the quantum yield of the Cdc42 mutant until it reaches 
saturation at roughly 80% of the original intensity. 
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PCP-bound Cdc42(Y32W, W97H) that saturated at about 20% (Figure 4C).  Identical 
experiments were carried out with GMP-PNP-bound Cdc42(Y32W, W97H) with 
similar results (not shown).  The NMR structure for GMP-PNP-bound Cdc42 
complexed to the CRIB domain of Pak1 shows that the nearest effector residue to 
position 32 in Switch I is approximately 12 Å away (16).  The same is true when 
examining the coordinates from the recently determined X-ray structure for Cdc42-
GMP-PCP bound to its limit-binding domain on Pak6 (PDB ID 2ODB).  Thus, the 
fluorescence changes seen upon the addition of the PBD construct are likely a direct 
reflection of effector-induced conformational changes that are specific for the GTP-
analog-bound forms of Cdc42. 
 
NMR studies of effector-induced changes in GTP-analog-bound forms of Cdc42- 31P-
NMR spectroscopy has proven to be very useful in studying the GTP-dependent 
activation of H-Ras in solution (23,24).  In particular, NMR studies led to the 
suggestion that the Ras-GMP-PNP complex exists in at least two conformational states 
(denoted as state 1 and state 2), as indicated by a split in the resonances of the β- and γ-
phosphates of the GTP-analog (23).  More recently, a similar split in the phosphate 
resonances was detected when NMR analysis was applied to H-Ras bound to GMP-PCP 
(24).  The addition of the limit Ras-binding domain (RBD) from either of two Ras-
effectors, namely the Raf kinase or Ral-GDS, then pushed the equilibrium toward state 
2.  Therefore, state 2 for H-Ras is considered to represent the signaling-active species as 
seen in the X-ray crystal structures for the GTP-analog-bound forms of the protein. 
Based on the crystal structure for the signaling-inactive Ras (T35S) – GMP-PNP 
complex, which lacks electron density for switch I, as well as 31P-NMR experiments for 
other inactivating mutations within Ras, state 1 is thought to represent an equilibrium of 
sub-states that are in fast exchange on the NMR-time scale that most likely are more 
closely related to the structure for GDP-bound Ras than GTP-bound Ras (28,29). Given 
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these findings with H-Ras, we were interested in performing a similar analysis of 
Cdc42.  As was done with H-Ras, we performed these experiments at 5˚C in order to 
slow-down any inter-conversion that might occur between different conformational 
states of Cdc42, so that they could be detected on the NMR time-scale.  However, 
unlike the case for H-Ras, when we analyzed the complexes of Cdc42 bound to either 
GMP-PNP or GMP-PCP, we detected only a single peak for each phosphate (Figures 
2.5A and 2.5B, respectively). These results indicated that the GTP-analog-bound forms 
of Cdc42 assume only a single detectable conformational state in solution.  Upon the 
addition of an equivalent molar amount of the PBD, conformational transitions were 
then detected in both the Cdc42-GMP-PNP (Figure 2.5A) and Cdc42-GMP-PCP 
(Figure 2.5B) complexes as indicated by shifts in the resonances for the γ-phosphate 
and to lesser extents for the β- and α-phosphates.  
31P-NMR studies of the H-Ras Switch I mutant, H-Ras(T35A), suggested that this 
mutant resides exclusively in the signaling-defective state 1, even after the addition of 
an effector protein (24,28,29). It seemed likely that the same would be true for Cdc42, 
given that the yeast Cdc42(T35A) mutant was shown to be unable to sustain cell 
proliferation, polarization or budding, and to be defective in binding to all known yeast 
Cdc42-effectors (30), and so we examined the phosphate resonances for the human 
Cdc42(T35A) mutant, in the presence and absence of the PBD.  Figure 2.5C shows that 
the resonances for the Cdc42(T35A)-GMP-PCP complex were slightly shifted when 
compared to those for GMP-PCP bound to wild-type Cdc42, suggesting that these two 
Cdc42 species may start-off in very similar, albeit subtly different, conformational 
states (Figure 2.5C).  However, importantly, the addition of the PBD did not cause a 
clearly detectable change in the positions of the peaks for the phosphate resonances for 
the GMP-PCP-bound Cdc42(T35A) mutant but only an overall broadening of the lines, 
whereas in the same experiment, the addition of the PBD caused obvious changes in the 
peak positions for the phosphate resonances for the GMP-PCP-bound wild-type Cdc42.  
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FIGURE 2.5 A-C  31P-NMR reveals that Cdc42 exists only in one conformation in solution 
but assumes another upon addition of an effector.  A, Cdc42-GMP-PNP (0.75 mM) with 
(top) or without (bottom) Pak3-PBD (0.75 mM) at 5˚C. B, Cdc42-GMP-PCP (1 mM) with (top) 
or without (bottom) Pak3-PBD (1 mM) at 5˚C.  A chemical shift of 1 ppm is seen for the γ-
phosphate upon addition of the effector.  Peaks are not split in any of the experiments implying 
Cdc42 has only one conformational state before binding the effector. C, Comparison between 1 
mM Cdc42(T35A)-GMP-PCP (top) and 1 mM Cdc42-GMP-PCP (bottom) with or without 1 
mM PBD. 
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These findings suggest that the GMP-PCP-bound Cdc42(T35A) mutant has a weaker 
affinity for the PBD due to the loss of stabilizing interactions from Thr35 to the Mg2+.  
 
Insights into the mechanism by which activated Cdc42 propagates signals to its downstream 
effector proteins- Based on the results from our fluorescence and NMR studies, it would appear 
that effector proteins play a major role in selectively inducing and/or stabilizing the signaling-
active conformational states of Cdc42. Various lines of evidence also indicate that both the 
signaling-inactive (GDP-bound) and signaling-active (GMP-PCP-bound) forms of Cdc42 have 
Switch regions that are highly mobile and likely encompass very similar, or at least overlapping, 
conformational equilibria (25,26).  This then raises a key question, namely, how are effectors 
able to distinguish between the GDP- and GTP-analog-bound forms of Cdc42, such that they 
interact with the latter Cdc42 species with high affinity? Given the plasticity of Switch I, it is 
possible that key residues such as Val36 or Phe37 may be oriented in such a way as to be 
recognizable to effectors, when Cdc42 is bound to either GDP or GTP-analogs.  However, 
presumably the effector would then only be able to engage the GTP-analog-bound form of 
Cdc42 in a manner that results in a high affinity, signaling-competent interaction.  Careful 
comparisons of the structure for Cdc42-GMP-PCP with those for different Cdc42-effector 
complexes (16,17,31,32) suggest how this might occur.  An example is shown in Figure 2.6A 
which compares the overall topology for the Cdc42-GMP-PCP complex with that determined 
from the X-ray structure for the complex between GMP-PNP-bound Cdc42(Q61L) and the 
effector protein Par6.  Although the two structures show little differences in Switch II, they 
highlight an obvious change in the Switch I effector loop.  These differences, when considered 
together with the available X-ray and NMR structures for other complexes between Cdc42 and 
effector proteins, suggest the following sequence of events for how effectors are able to 
selectively bind with high affinity to the GTP-bound state of Cdc42.  The first step involves the 
formation of a small hydrophobic pocket that buries either Switch I residue Phe37 or Val36, or 
both. Figure 2.6B depicts this step for Par6, while Figure 2.6C shows another example for one  
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FIGURE 2.6 A-D  Effector proteins stabilize Switch I in an “active” conformation.  
A, Comparisons of the overall fold of GMP-PCP-bound Cdc42 versus GMP-PNP-bound 
Cdc42(Q61L) complexed to Par6 (PDB ID 1NF3).  B, Switch I residues Thr35 and 
Phe37 for Cdc42(Q61L)-GMP-PNP bound to the non-conventional Cdc42/Rac-
interactive-binding domain of Par6 are shown in grey.  Par6 residues (in green) form the 
lid to a hydrophobic pocket for Phe37, with the bottom of the pocket being contributed 
by residues from Cdc42 (grey).  Phe37 acts as a fulcrum to flip Thr35 into position to 
coordinate the Mg2+.  An overlay of Thr35 and Phe37 from Cdc42-GMP-PCP is 
displayed in blue to illustrate the lever action and stabilization of Phe37 by Pak.  C, The 
same view of Cdc42-GMP-PNP bound to the CRIB domain of Pak1 based on the NMR 
structure for this complex (PDB ID 1E0A). Phe37 is embedded in a hydrophobic pocket 
created by both Pak1 (green) and Cdc42(Q61L) (grey).  D, Overlay of Switch I from the 
NMR structure for the Cdc42-GMP-PNP-Pak1 complex (PDB ID 1E0A) and the X-ray 
structure for the Cdc42-GMP-PCP complex.  Notice that in the Pak1 complex, Switch I 
residues from Cdc42 are rotated 180° from their position in the Cdc42-GMP-PCP 
structure and are stabilized by the interaction of Phe37 with the effector protein. 
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of the better-known effectors for Cdc42, Pak1 (p21-activated kinase-1).  In both of these cases, 
residues from the effector proteins (shown in green) contribute to the lid of the binding-pocket, 
while residues from Switch II of Cdc42 (shown in gray) form the bottom of the pocket.  The 
potential role for the hydrophobic pocket is to stabilize Switch I residues, and in particular, to 
enable Phe37 to act as a lever to flip Switch I, effectively reversing the orientations of key 
residues when compared with the signaling-inactive (GDP-bound) forms of the protein.  This 
rearrangement, which is depicted in Figure 2.6D for the case of Cdc42 binding to Pak1, allows 
Tyr32 as well as Thr35 to coordinate the γ-phosphate and Mg2+ ion, respectively, and to lock the 
signaling-active conformation in place.  When the nucleotide in the binding pocket is GDP 
(instead of GTP), the absence of the γ-phosphate would not allow these stabilizing interactions 
with Switch I residues, and as a result, the effector is not able to bind with high affinity.  
Likewise, the Cdc42(T35A) mutant, which lacks the critical Switch I threonine residue, is 
defective in its ability to assume a stable activated conformational state in the presence of 
effector proteins (Figure 2.5C). 
It should be noted that this pattern of recognition of the GTP-bound state of Cdc42 
is also used by the Cdc42-GAP (33).  In this case, residues from the GAP together with 
Switch II form a pocket that buries Phe37, with a network of interactions involving 
Arg305 from the GAP (i.e. the 'arginine finger') linking Switch I and Switch II residues 
with the γ-phosphate. 
 
 
DISCUSSION 
 
Structural studies performed on H-Ras and various members of the large 
heterotrimeric G-protein family demonstrated that there were two conserved regions 
(Switch I and Switch II) that changed conformation upon GDP-GTP exchange (11-14).  
These conformational “hot-spots” have been assumed to represent the basis by which 
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G-proteins act as molecular switches in cellular signaling pathways, by binding and 
regulating the activities of their biological effectors. GMP-PCP-bound Cdc42 is able to 
recognize effector proteins similar to other signaling-active forms of Cdc42 that contain 
bound GTP or other GTP-analogs, and in a manner distinct from the signaling-inactive 
GDP-bound Cdc42.  Thus, it was surprising when we determined a high-resolution X-
ray crystal structure for Cdc42 bound to the GTP-analog GMP-PCP and found that it 
was virtually identical, including its Switch I and Switch II regions, to the 
corresponding structures for signaling-inactive, GDP-bound forms of the protein [i.e. 
both wild-type Cdc42-GDP and Cdc42(G12V)-GDP]. 
Studies performed in solution further supported the conclusions that we reached 
from an analysis of the X-ray structures.  We introduced a tryptophan residue at 
position 32 within Switch I, in order to use its intrinsic fluorescence properties as a 
conformational monitor for changes that occur within this region of Cdc42 following 
GDP-GTP exchange, as well as upon the ensuing binding of an effector protein.  In 
these studies, we saw little if any change in the Switch I conformation of Cdc42 when 
comparing the GDP- and GMP-PCP-bound states of the protein (i.e. on the order of at 
most 5-10%).  Here again this differed from the case for H-Ras, as we and others have 
been able to detect more significant differences in the Switch I conformation (i.e. > 
30%) when using a similar fluorescence read-out to compare the GDP- and GTP-
analog-bound states of the protein. We then showed by using 31P-NMR spectroscopy 
that unlike the case for H-Ras, where two distinct states were detected for GTP-analog-
bound forms of the G-protein (24,28,34), with one of these apparently representing the 
signaling-active state, both the GMP-PNP- and GMP-PCP-bound forms of Cdc42 
exhibited only a single (non-activated) conformational state.  
Despite the structural similarities between the GDP- and GMP-PCP-bound forms of 
Cdc42, effector proteins are able to distinguish between these two species.  When the 
limit-binding domain of Pak3 was added to the GMP-PCP-bound form of the 
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Cdc42(Y32W, W97H) protein, a clear change in the fluorescence emission from the 
Switch I tryptophan residue was observed, whereas, the effector protein had no effect 
on the fluorescence emission of the GDP-bound Cdc42(Y32W, W97H) mutant.  The 
addition of the effector protein also caused shifts in the phosphate resonances for the 
GMP-PCP- and GMP-PNP-bound forms of Cdc42, as read-out by NMR spectroscopy.  
The latter findings are consistent with various other lines of evidence from NMR 
studies. The NMR-derived structures for different activated forms of Cdc42 bound to 
WASP (Wiscott-Aldrich Syndrome Protein), Pak, and Ack (Activated Cdc42-associated 
kinase), showed no resonances for either the Switch I or Switch II regions of Cdc42, 
prior to the addition of the effector protein (16,31,32,35). This was attributed to the 
dynamic nature of these regions.  However, upon the addition of a Cdc42-effector 
protein, the resonances for these regions then became clearly defined (16,31,32,35).  
Additionally, Oswald and colleagues demonstrated in NMR studies that Switch I and 
Switch II contained significant flexibility and exhibited rapid conformational exchange 
in both the GDP- and GMP-PCP-bound forms of Cdc42, and that this flexibility was 
reduced in the Cdc42-GMP-PCP species upon the binding of an effector (26). 
Taken together, these findings highlight the strong influence exerted by effector 
proteins on Cdc42 and its ability to assume signaling-active conformational states.  
However, the role of effector proteins in influencing such conformational transitions is 
not restricted to Cdc42, as fluorescence and NMR studies have shown that effectors also 
affect the signaling-active states of H-Ras (24,28,29,36-38).  As alluded to above, the 
results from NMR experiments showed that upon binding GTP-analogs, H-Ras can 
exist in two stable conformational states. The majority of the GTP-analog-bound H-Ras 
population appeared to assume what was felt to be a signaling-active conformational 
state (state 2), with the remainder of the H-Ras molecules being in a signaling-inactive 
conformation (state 1). The binding of the limit-functional domain from a Ras-effector 
(e.g. the Raf serine/threonine kinase) then promoted and/or stabilized the signaling-
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active state 2 conformation, such that the total H-Ras population assumed this state in 
the presence of the effector (24). Interestingly, the NMR results reported for M-Ras 
were similar to what we have seen for Cdc42; specifically, GMP-PNP-bound M-Ras 
showed only a single stable conformational state as detected by 31P-NMR, which was 
then altered upon the addition of the effector protein, Raf (36).  Still, the X-ray crystal 
structures for the GDP- and GMP-PNP-bound forms of M-Ras showed changes in 
Switch I.  The authors concluded that upon binding GTP-analogs, essentially the entire 
pool of M-Ras adopts the signaling-inactive state-1 conformation originally described 
for H-Ras, and that the binding of effector proteins then drives the GTP-analog-bound 
forms of M-Ras entirely to the signaling-active state-2 conformation.  What 
distinguishes the findings that we report here for Cdc42 is that both the state-1 and 
state-2 conformations for the GTP-analog-bound Ras proteins can be structurally 
distinguished from GDP-bound Ras, whereas we are able to detect little if any structural 
differences between the GDP- and GMP-PCP-bound forms of Cdc42. Nonetheless, 
effector proteins are able to distinguish between these two forms of Cdc42.   
An important question concerns whether the apparent strong reliance exhibited by 
Cdc42 for effector-induced conformational changes occurs in cells with the 
physiologically relevant, activating nucleotide GTP.  In fact, it has been shown that the 
equilibrium constants for the inter-conversion between the inactive- and active-states of 
H-Ras, as measured by 31P-NMR (i.e. states 1 and 2, respectively), are lower for H-Ras 
bound to GMP-PCP or GMP-PNP when compared to GTP (24).  It was postulated that 
the increased amount of GTP-analog-bound H-Ras molecules that are in the signaling-
inactive state 1 conformation, compared to when H-Ras is bound to GTP, might be due 
to a loss of an important interaction between the P-loop and the bridging oxygen from 
GTP, or the result of the increased pKa on the γ- and β-phosphate groups in the non-
hydrolyzable analogs. The latter could have an effect on the ability to form hydrogen 
bonds to key residues on Switch I.  We have tried to use fluorescence spectroscopy to 
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see whether Cdc42 might behave differently when bound to GTP, compared to the non-
hydrolyzable analogs GMP-PCP or GMP-PNP.  Thus far, these experiments have been 
inconclusive.  Similar to what we have seen with the non-hydrolyzable GTP analogs, 
we have been unable to detect a significant difference in the fluorescence emission from 
Trp32 between the GDP-bound and GTP-bound Cdc42(Y32W, W97H) species.  
However, as yet we have not been able to observe reliable differences in the Trp32 
fluorescence upon the addition of the limit-binding domain of Pak3.  At least part of the 
challenge in making interpretations from these experiments comes from the fact that 
Cdc42 shows a significantly higher intrinsic GTP hydrolytic activity compared to H-
Ras (39), which may obscure differences, such as those induced by effector proteins. 
Still, the fact that effectors have a clear and substantial influence on the final 
conformational state that Cdc42 is able to assume in the presence of non-hydrolyzable 
GTP-analogs that are signaling-competent, leads us to believe that effector proteins will 
play a similarly important role for GTP-bound Cdc42 in the cell. 
All of this leads to yet another interesting question, namely how do effector proteins 
select between the GDP- and GTP-bound forms of Cdc42, so as to ensure that signals 
are only transmitted when this G-protein is in the GTP-bound state?  We obtained some 
clues toward answering this question when considering the available structures for 
GTP-analog-bound forms of Cdc42 in complexes with the limit domains of different 
effector proteins.  For each of these cases, the effector provides a binding pocket for 
Phe37 of Switch I of Cdc42, which then leads to an interaction between Thr35 from 
Switch I and the γ-phosphate of the GTP-analog.  In solution, the Switch I loop of 
Cdc42 is highly mobile and is likely able to interconvert between different 
conformations representing local minima on the energy landscape. Some of these 
minima may represent signaling conformations that can be reached by both the GDP- 
and GMP-PCP-bound proteins and enable the proper presentation of Phe37 to be 
“captured” by the effector protein. Once this occurs, it creates a domino effect whereby 
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important residues such as Thr35 as well as Tyr32 are brought into close contact with 
the nucleotide.  The net outcome is that Cdc42 is locked into a complex with the 
effector, but only when it contains the γ-phosphate of GTP. 
The role played by Phe37 in forming a high affinity complex with effectors 
probably explains our earlier observations that this residue is essential for Cdc42-
coupled signaling events linked to cell growth and cellular transformation (40).  Also in 
support of this model, we showed in NMR studies that the GMP-PCP-bound 
Cdc42(T35A) mutant was not able to respond to effectors in the same way as the wild-
type Cdc42-GMP-PCP complex. Specifically, the addition of the PBD to GMP-PCP-
bound Cdc42(T35A) did not cause distinct shifts in the phosphate resonances, unlike 
the case for the wild-type Cdc42-GMP-PCP species, but did cause some line 
broadening. This suggests that the effector is able to interact with the Cdc42(T35A)-
GMP-PCP complex but with a much weaker affinity compared to GMP-PCP-bound 
wild-type Cdc42. Therefore, in the absence of the critical Switch I Thr35 residue, the 
GMP-PCP-bound Cdc42 mutant was unable to be locked into a high affinity, signaling-
active conformational state by the effector.  The fact that we observed slightly different 
peak positions for the phosphate resonances from the Cdc42(T35A)-GMP-PCP 
complex versus the Cdc42-GMP-PCP complex would suggest that these two Cdc42 
species do not share identical conformational profiles, even though they both exist 
primarily in signaling-inactive states.  What nonetheless seems clear from comparisons 
of the X-ray structures for the GDP- and GMP-PCP-bound forms of Cdc42, as well as 
from fluorescence and NMR studies, is that the spectrum of conformational states for 
these different nucleotide states of Cdc42 must overlap and that the Switch 
conformations for the wild-type Cdc42-GMP-PCP complex and the GDP-bound Cdc42 
species are more closely related than those for GMP-PCP-bound Cdc42 before and after 
the binding of effectors.  
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The results that we have obtained regarding the conformational status of the Switch 
regions of Cdc42 in response to GDP-GTP exchange, versus the changes induced by 
biological effectors, are consistent with the biochemical and structural analyses of the 
interactions of Cdc42 with RhoGDI.  Both the GDP- and GTP-bound states of Cdc42 
are regulated by RhoGDI, such that the GDI significantly slows their rates of GDP 
dissociation and GTP hydrolysis (41,42).  Fluorescence measurements have shown that 
RhoGDI binds to the GDP- and GTP-bound forms of Cdc42 with identical affinities 
(43). This can be explained by the fact that Switch II looks identical when comparing 
the X-ray crystal structure for the Cdc42-GDP-RhoGDI complex (44) with that for 
GMP-PCP-bound Cdc42.  Switch II represents the initial site of contact for RhoGDI 
and so the lack of any detectable change in this region when comparing GDP- and GTP-
bound forms of Cdc42 would be consistent with the inability of the GDI to distinguish 
between these different states of the G-protein.  What is especially interesting is that 
Switch II also shows little or no change when comparing the GDP- and GTP-bound 
forms of Cdc42 with any of the reported X-ray crystal structures for Cdc42 complexed 
to effector proteins.  
Given these findings, it becomes interesting to consider whether G-proteins related 
to Cdc42 might show a similar behavior with regard to their Switch domains, and thus 
rely heavily on effector proteins to induce the necessary changes to ensure signal 
propagation.  One such related G-protein is Rac1, which is 68% identical to Cdc42 and 
shares some of the same effector proteins.  In the case of the X-ray crystal structure for 
GMP-PNP-bound Rac1, Switch I residues Tyr32 through Val36 exhibited poor electron 
density and consequently this region was modeled in the completed structure by using 
data from the related Dictyostelium discoideum protein Rac1a (45).  This makes it 
difficult to know with certainty whether Switch I changes in the X-ray crystal structures 
for the GTP-analog- and GDP-bound forms of Rac1.  However, it is interesting that the 
X-ray structures for the GDP- and GMP-PNP-bound forms of Rac1, when complexed to 
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the putative Rac-effector Arfaptin, are nearly identical (46).  Moreover, Thr35 from 
Switch I does not participate in coordinating the Mg2+ ion in either the GDP- or GMP-
PNP-bound Rac1-Arfaptin structures, which is in contrast to what is typically seen in 
the structures of all small G-proteins when they are in their signaling-active states.  
These results would seem to suggest that GDP-GTP exchange on Rac1 is not sufficient 
to induce significant conformational changes within the Switch I region of the protein.   
The X-ray crystal structures for the GDP- and GTP-analog-bound forms of RhoA 
show that changes in the Switch I loop do occur within this G-protein as an outcome of 
GDP-GTP exchange (47).  On the other hand, our recent studies with RhoC suggest that 
it can exist in multiple activated-states, and that the effector protein again influences the 
final conformational states that are reached and necessary for signal propagation (48).  
Thus, it is becoming increasingly clear that a spectrum of possibilities exist 
regarding how G- proteins reach the conformational states that are necessary for signal 
propagation.  At one end of the spectrum are the α subunits of large G-proteins (Gα 
subunits), for which the conformational changes necessary for signal propagation may 
be entirely driven by GDP-GTP exchange. Indeed, the ability of Gα subunits to undergo 
such conformational transitions is necessary for their signaling function, as the GDP-
bound Gα subunits are tightly associated with their partner Gβγ complexes and 
movements in Switch II that accompany GDP-GTP exchange are thought to be 
necessary to reduce the affinity of Gβγ and enable the GTP-bound Gα subunit to engage 
its downstream signaling effector.  For the case of H-Ras, GDP-GTP exchange may be 
sufficient to induce differences in Switch I and Switch II within a significant population 
of the G-protein molecules that can be recognized by many of their effector proteins.  A 
number of these effectors (e.g. Raf, PI 3-kinase, Ral-GDS) appear to use a very similar 
mode of binding and so each might even be able to recognize the same GTP-induced 
conformational state within the G-protein (49).  Still, the principle site for effector-
binding in Ras (Switch I) is a highly flexible region, given that two conformational 
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states have been detected for GTP-analog-bound forms of H-Ras from NMR studies, 
such that the binding of effectors can induce and/or stabilize one of these states and 
thereby ensure that the vast majority of GTP-analog-bound H-Ras molecules are in a 
signaling-active conformation (24).  
Cdc42 may represent an example of a G-protein that is at the other end of the 
spectrum, as its GTP-bound state appears to be strongly receptive to effector-induced 
conformational changes.  It may be especially important that the effector-binding site on 
Cdc42 shows significant plasticity, given that the GTP-bound form of this protein 
engages a number of different cellular effectors.  Moreover, Cdc42 needs to move 
between distinct cellular compartments to activate specific effector proteins (e.g. 
between the plasma membrane and Golgi), and this movement may be mediated by 
RhoGDI, which, as alluded to above, binds to both the signaling-inactive and signaling-
active forms of the G-protein (3).  Thus, the ability of individual effector proteins to 
mold Cdc42 into a favorable conformational state for different signaling events, would 
be highly advantageous by providing maximum flexibility for a G-protein that needs to 
switch on a number of effector activities located at different sites within the cell.  
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Chapter 3 
 
THE CONSTITUTIVELY ACTIVATED MUTANT CDC42 (Q61L) DOES NOT 
REQUIRE AN EFFECTOR PROTEIN TO INDUCE THE FULLY 
ACTIVATED CONFORMATION 
 
Introduction 
 G proteins are one of the most important families of proteins in the human 
genome. They are often referred to as molecular switches, turning specific cellular 
signaling pathways on and/or off at the appropriate time. G proteins are involved in 
nearly every major cellular process including, but not limited to, cellular growth, 
differentiation, trafficking, and apoptosis. G proteins are activated by binding cellular 
GTP and deactivated by hydrolyzing GTP to GDP and Pi. Once bound to GTP, the G 
protein is able to interact with downstream effectors which usually starts a signaling 
cascade whose overall outcome is determined by the pathway. As might be expected, 
G proteins themselves are highly regulated, both temporally and spatially, by GEFs 
(Guanine nucleotide Exchange Factors) and GAPs (GTPase Activating Proteins). 
Deregulation of many G proteins either by mutation or gene expression, can lead to 
varied disease states including cancer. In fact, one of the first known oncogenes 
discovered was the small G protein Ras (1,2). 
 Ras became the subject of intense research once its role in human cancers was 
established and, as a result, it was one of the first G protein structures to be solved by 
x-ray crystallography (3). Since that time, numerous G protein structures have been 
solved from both the large and small G protein families, providing us with invaluable 
mechanistic information. One of the mechanistic paradigms that came from this work 
is the structural rearrangement of two “switch” regions named switch I and II (loops 2 
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and 4 respectively in Ras nomenclature) upon activation by GTP (4). These structural 
rearrangements were later proven to be present in all G protein families for which 
structures are available. It was assumed that these structural rearrangements were the 
basis for cell signaling as the G protein would cycle between an effector-recognizable, 
signaling-competent GTP-bound state and a signaling-defective GDP-bound state. 
Supporting evidence came in the form of numerous structures for activated G proteins 
bound to the limit binding-domains of various effectors where the main binding 
interface was in fact the switch regions. 
 With this as a backdrop, we previously reported the first known structure of a 
signaling-active G protein, Cdc42-GMP-PCP, which was virtually identical to its 
signaling-inactive counterpart, Cdc42-GDP (81). We showed conclusively that this 
protein was biologically active by its ability to complex with the Cdc42 limit binding-
domain (CBD) of its effector Pak3 in vitro. These findings were surprising and led us 
to the natural question of how targets for Cdc42 are able to distinguish between the 
GTP-bound and GDP-bound forms of the protein. One seemingly plausible 
explanation was the theory of induced-fit first proposed for the action of enzymes in 
the late 1950s (5). Simply stated, the theory asserts that a substrate can induce 
conformational rearrangements in its binding partner that drives the final structure of 
the enzyme-substrate complex toward a fully catalytic state. It seems likely that this is 
also the case for Cdc42 where in the absence of a target/effector protein, the switch 
regions in both the GDP- (inactive) and GMP-PCP-bound (active) forms assume 
similar, if not identical, conformations. Under such conditions, Cdc42 can be thought 
of as existing in an “open” state denoted by the absence of contacts between the γ-
phosphate of GTP and key switch I residues, specifically Tyr32 and Thr35. After the 
addition of an effector protein, a conformational rearrangement is induced and/or 
stabilized which is characterized by switch I assuming a “closed” state as seen in the 
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x-ray structure for Cdc42 complexed with the Cdc42 binding-domain from Par6 (6). In 
this structure, as well as a number of NMR structures of Cdc42 bound to the limit-
binding domains from various effectors, the “closed” state is characterized by 
interactions between switch I residues Tyr32 and Thr35 with the γ-phosphate and 
Mg2+, respectively, and is very similar to the structures of activated Ras and other 
small G proteins (7-9).         
 Through the use of fluorescence spectroscopy and 31P-NMR, we were able to 
show that GTP-analog-bound forms of Cdc42 undergo an effector-induced conversion 
from a GDP-like conformational state to a signaling-active state. In addition, we found 
that in solution, activated Cdc42 adopts only one discernable conformation which is 
thought to resemble the “open” GDP-like state. However, upon the addition of an 
effector protein, the total population of Cdc42 molecules shifted to the activated state 
as described in the “closed” conformation. 
 Two of the questions that arose from our structural studies for Cdc42 bound to 
GMP-PCP were; does an activated mutant of Cdc42 (i.e. Cdc42 (Q61L)), when bound 
to GMP-PCP, assume a signaling-inactive (“open”) or signaling-active (“closed”) 
conformation and what are the effects of the physiologically relevant nucleotide GTP 
on Cdc42 activation? The second question arises from the fact that there has been 
evidence in the literature to suggest that different nucleotide analogs may activate G 
proteins differently depending on the bridging atom between the β-γ-phosphate (10-
12). To this end, we provide structural evidence that Cdc42 (Q61L) – GMP-PCP, 
unlike wild-type, assumes a classic activated switch I architecture where Thr35 and 
Tyr32 are in close contact to the Mg2+ and γ-phosphate respectively. We further show 
that GTP behaves like its non-hydrolyzable GTP-analogs GMP-PCP and GMP-PNP, 
since it shows little capability, in the absence of effector proteins, to induce a 
signaling-active conformational state in Cdc42.              
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Experimental Procudures 
Protein Purification-  Cdc42 (Q61L) was expressed in BL-21 bacterial cells from a 
pET-15b plasmid. IPTG (Isopropyl-β-D-1-thiogalactopyranoside) was added to a final 
concentration of 1 mM when the cells reached an O.D. of 0.6 at 600 nm and cells were 
allowed to grow for another 3 hours. Cells were lysed in 1 x HMA (20 mM HEPES 
pH 8.0, 5 mM MgCl2, 0.1 mM Na-Azide) supplemented with ~2 μM benzamidine,    
~20 μM PMSF (phenylmethanesulphonylfluoride), ~50 ng/μl aprotinin and leupeptin, 
by sonication and cleared lysates were briefly incubated with nickel beads. The nickel 
beads were washed with 250 ml of 1 x HMA with 20 mM imidazole and 500 mM 
NaCl and then with 1 x HMA alone. Protein was eluted in 70 ml of 1 x HMA 
supplemented with 200 mM imidazole. The eluent was concentrated to ~ 30 ml, 
incubated at 4˚C overnight with thrombin (Haematological Technologies Inc.), and 
then chromatographed on a 5 ml Hi-Trap Q column (Amersham) eqilibrated with 1 x 
HMA. The flow-through was collected and concentrated. Nucleotide exchange was 
carried out by incubating the G protein with a 5-fold molar excess of GMP-PCP in the 
presence of 200 mM ammonium sulfate and 100 U of alkaline phosphatase beads 
(Sigma # P0927) for ~4 hours at 4˚C. The flow-through from the reaction was 
collected and the beads were washed 3 times with 1 x HMA. The eluent was then 
chromatographed on a G-75 gel filtration column (Amersham) and concentrated to 80 
mg/ml. Purified proteins were snap-frozen in liquid nitrogen and stored at – 80˚C. 
Crystallization conditions were found by use of a PEG ion screen (Hampton 
Research) and further pH refinement. Optimal crystallization conditions required 5% 
PEG 4K, 100 mM citric acid, pH 3.0. Crystals were obtained by the hanging drop 
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method. Prior to data collection, crystals were soaked in mother liquor containing 20% 
glycerol and frozen in liquid nitrogen.  
Data Collection and Processing- Data was collected with a rotating anode x-ray 
generator using a Rigaku R-AXIS IV image plate detector with a 0.5˚ oscillation step, 
and a 15 minute exposure time. Data was processed using d*Trek (13). Rotation and 
translation searches were performed using CNS as well as structure refinement (14). 
Cdc42 (1ANO) with the GDP removed was used as the search model and correct 
phases were assessed by the presence of clear electron density for the GMP-PCP 
moiety. The final structure was validated with Procheck (15). The final statistics are 
presented in Table 2. 
31P-NMR- Samples were prepared by dissolving Cdc42 (1 mM) pre-exchanged with 
GMP-PNP or GMP-PCP, either with or without the limit Cdc42-binding domain from 
PAK3 (PBD) (1 mM), in HMA-containing 10% D2O.  31P spectra were obtained at 
5˚C on a Varian INOVA spectrometer operating at 202.37 MHz using a 5 mm Varian 
DBG probehead. 1H broadband decoupling was applied throughout the acquisition.  A 
relaxation delay of 8 seconds was used between scans, with 3000 - 4000 scans 
summed prior to analysis.  Data was zero-filled to 128k points and an exponential 
multiplication (5 - 10 Hz) was performed prior to Fourier Transform.  Spectra were 
referenced externally to 85% phosphoric acid (0 ppm). 
 
Results 
Structure of the Cdc42 (Q61L) – GMP-PCP complex 
The x-ray crystal structure for the Cdc42 (Q61L) – GMP-PCP complex conforms 
to the same structural fold as that exhibited by GMP-PCP-bound, wild-type Cdc42 
(16) as well as those for other Rho family members in general. It is composed of 6  
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TABLE 2 
           
 
           a Rsym = Σhkl Σi[Ii(hkl) - <I(hkl)>]/ΣhklΣi(hkl) 
           b Rfree and Rcrys = Σ|Fobs – Fcalc|/ ΣFobs 
 
Data Statistics 
Resolution Range (Å)                                 51  -  2.0 
Rsyma, % overall (last shell)                         4.4   (26) 
Completeness (%), overall (last shell)        98.4 (87.8) 
Multiplicity, overall (last shell)                  6.12 (4.2) 
Total no. of refections                                 363873 
No. of unique reflections                             59471 
I/sigI, overall (last shell)                              17.1 (3.8) 
Refinement Statistics 
Rfreeb, (%), overall (highest shell)                 22 (48) 
Rcrystb (%), overall (highest shell)                 21 (45) 
Ramachandran Plot 
Residues in most favored (%)                      93.5 
Residues in allowed regions (%)                   6.2 
Residues in generously allowed regions (%) 0.3 
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β-sheets arranged in a β-sandwich motif surrounded by 6 α-helices and a small 3/10 
helix just before the Rho - insert region (residues 120-132). The guanine-nucleotide is 
bound to Cdc42 (Q61L) in a similar fashion to nearly all other G proteins. The tri-
phosphate tail is stabilized by an extensive hydrogen bond network to key residues in 
both switch I and II (residues 30-38 and 60-76 respectively), as well as residues in the 
P-loop (residues 10-18). Specific to activated forms of most G proteins, the γ-
phosphate is hydrogen bonded to the backbone amides from Thr35 as well as Gly60, 
in addition to making hydrogen bonds to the hydroxyl group from the side-chains of 
Tyr32, Thr35, as well as the ε-amino group from Lys16. These interactions with 
switch I residues Tyr32 and Thr35 appear to be most important for stabilization of the 
activated conformation of the protein. The guanine base is stabilized by contacts with 
the carboxyl side-chain of Asp118, which is part of the TQID motif (NKXD in Ras), 
as well as with the backbone amides from Ala159 and Leu160. The guanine ring is 
further stabilized through π-stacking interactions with Phe28.  
 
Comparison between Cdc42 – GMP-PCP and Cdc42 (Q61L) – GMP-PCP 
The x-ray crystal structure for the Cdc42 – GMP-PCP complex revealed a switch I 
architecture identical to previous structures for the signaling-inactive Cdc42 – GDP 
complex (1ANO), as well as Cdc42 (G12V) – GDP (1A4R). In comparison with these 
structures, the Cdc42 (Q61L) – GMP-PCP complex is significantly different in one 
very important region. Switch I in Cdc42 (Q61L) – GMP-PCP has now rearranged to 
cover the nucleotide-binding pocket and coordinate to the Mg2+ and γ-phosphate in a 
similar manner to what has been reported for the effector-bound structures for Cdc42 
(Fig 3.1A-C). Differences between the Cdc42 – GMP-PCP and Cdc42 (Q61L) – 
GMP-PCP structures occur between Pro29 and Asn39 encompassing all of switch I. 
Phenylalanine 37, which is important for the binding of many effectors, is observed to  
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Figure 3.1 X-ray crystal structures of signaling active Cdc42 complexes. A, Switch 
I and II from the Cdc42 – GMP-PCP complex reveal an inactive GDP-like structure. 
Threonine 35 and tyrosine 32 are positioned toward the solvent and are unable to 
interact with the nucleotide. B, Switch I and II from the constitutively activated Cdc42 
(Q61L) – GMP-PCP x-ray crystal structure reveal an activated structure. Threonine 35 
and tyrosine 32 are coordinated to the Mg2+ and γ-phosphate respectively, which is a 
hallmark of G protein activation. C, Switch I and II for an activated, effector-bound 
Cdc42 (Q61L) structure. Comparison of the Switch regions with the Cdc42 (Q61L) – 
GMP-PCP complex alone (3.1B) reveals a virtually identical architecture. 
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be rearranged so as to now face toward the solvent as opposed to facing toward the 
nucleotide-binding pocket as is the case for the Cdc42 – GMP-PCP complex. As a 
consequence of this rearrangement, switch I has shifted its position by not only folding 
over the guanine nucleotide-binding pocket, but also by translating roughly one 
residue toward the C-terminal end. This has the effect of extending the intra-molecular 
β-sheet between β strands 2 and 3 by two hydrogen bonds. Specifically, hydrogen 
bonds form between the main-chain carbonyl and amide group from Asp38 to the 
main-chain amide and carbonyl group from Asp57, respectively (Fig 3.2A-C). An 
additional hydrogen bond is formed between the main-chain carbonyl oxygen from 
Val36 to the amide nitrogen from Ala59. These hydrogen bonds connect switch I with 
the highly conserved switch II D57XXG60 motif. The net effect of this is to create a 
larger binding platform for effector proteins. All known structures for Cdc42 
complexed with effectors share a common structural binding motif whereby an 
intermolecular β-sheet is formed between the effector and β2 from Cdc42, which 
includes the extended area. 
Switch II reveals subtle differences between the two structures. A slight shift of  
~0.5 Å is observed for the D57XXG60 residues that have been implicated in the binding 
of guanine nucleotides, i.e. Ala59 and Gly60. Gly60 is hydrogen bonded to the γ-
phosphate in both structures. As a result of the shift, Gly60 in the Cdc42 (Q61L) – 
GMP-PCP complex is closer to the γ-phosphate compared to its position in the wild-
type complex (i.e. 2.71 Å versus 3.28 Å) and thus has a stronger interaction with the γ-
phosphate.  
Perhaps the most notable difference between the structures for switch II in the 
Cdc42 (Q61L) – GMP-PCP and Cdc42 – GMP-PCP complexes resides in the 
orientation of the side-chain of Leu61 from Cdc42 (Q61L) – GMP-PCP. In the Cdc42 
– GMP-PCP complex, Gln61 faces toward the nucleotide and makes a hydrogen bond  
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Figure 3.2 A-C Activation of Cdc42 (Q61L) provides a larger binding platform 
for interactions with effector proteins. The inter-switch region between switch I and 
II is composed of β-strands 2 and 3 which form a β-sheet. A, The signaling-active 
structure for Cdc42 – GMP-PCP (green) reveals a break in the β-sheet as it approaches 
switch I. This break is attributable to the lack of switch I interactions with the GTP-
analog which does occur in the activated Cdc42 (Q61L) – GMP-PCP structures. B, 
The Cdc42 (Q61L) – GMP-PCP complex reveals a β-sheet which is extended by two 
hydrogen bonds when compared to the Cdc42 – GMP-PCP complex (A). This 
extension creates an important binding platform for effector proteins. C, X-ray crystal 
structure for Cdc42 (Q61L) – GMP-PNP bound to the limit binding domain of Par6 
(pbd i.d. 1NF3) is an example of how effector proteins bind. All structures for effector 
proteins bound to Cdc42 reveal an intermolecular β-sheet between the effector protein 
and Cdc42 in the region of the extended β-sheet.       
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with the γ-phosphate. In contrast, Leu61 in the Cdc42 (Q61L) – GMP-PCP complex 
faces away from the negatively charged γ-phosphate (Fig. 3.3). However, a water 
molecule in the Cdc42 (Q61L) – GMP-PCP structure is seen to occupy the same 
position as the Gln61 side-chain in the wild-type complex and is hydrogen bonded to 
the γ-phosphate. 
The temperature factor for Leu61 in the Cdc42 (Q61L) – GMP-PCP complex is 
not significantly higher than the temperature factors for neighboring residues and is in 
fact lower than the average overall temperature factor for the total structure, indicating 
that this conformation is quite stable. Looking carefully, this stability is imparted by 
the fact that Leu61 is situated as the first residue of a β-turn and as such, its main-
chain carbonyl group is hydrogen bonded to the main-chain amide from Tyr64 as well 
as to the side-chain guanidinium group from Arg68. In addition, the aliphatic side-
chain from Leu61 makes van der Waals contacts with the polar side-chains of other 
residues within the β-turn and is therefore sandwiched between the highly charged γ-
phosphate on one side and the polar side-chains from the other β-turn residues on the 
other. This point is illustrated by the fact that although residue Leu61 in the Cdc42 
(Q61L) – GMP-PCP complex is facing in the opposite direction from Gln61 in the 
Cdc42 – GMP-PCP structure, the difference between the solvent accessibilities of the 
two residues is only 5%, (i.e. 22% versus 17%, respectively).   
 
 
Comparison of the structure of the Cdc42 (Q61L) – GMP-PCP complex with those for 
activated Cdc42-effector complexes 
Comparisons of the rotomeric conformational state of residue 61 between the x-ray 
crystal structures for Cdc42-effector complexes versus the Cdc42 (Q61L) – GMP-PCP 
complex, reveals a multitude of conformations that range from Gln61 
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Figure 3.3 Comparison of Gln61 and Leu61 between Cdc42 – GMP-PCP and 
Cdc42 (Q61L) – GMP-PCP respectively. Cdc42 – GMP-PCP is depicted in green 
and Cdc42 (Q61L) – GMP-PCP is depicted in orange. Glutamine 61 is an important 
residue for GTP hydrolysis. It is thought to function by helping to orient a 
nucleophillic water molecule for an in-line attack on the γ-phosphate during the 
hydrolysis reactions transition state. In the Cdc42 – GMP-PCP complex, it is seen to 
hydrogen bond to the γ-phosphate allowing it to be in a more favorable position for the 
hydrolysis reaction. Mutation of Gln61 to leucine results in a reorientation of the 
leucine side-chain away from the nucleotide binding pocket. However, a water 
molecule (red) from the Cdc42 (Q61L) – GMP-PCP complex is observed to replace 
the lost hydrogen bond from the Cdc42 – GMP-PCP complex. 
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facing towards the γ-phosphate, as seen in the Cdc42 – GMP-PCP complex, to the 
extreme where the side-chain of Leu61 is facing in the opposite direction in the Cdc42 
(Q61L) – GMP-PCP complex. In agreement with the x-ray and NMR structures of 
activated forms of Cdc42 in complex with different effectors and regulators (6-8,17-
19), switch I within the Cdc42 (Q61L) – GMP-PCP complex is rearranged to 
coordinate to the Mg2+ as well as to the γ-phosphate from the GTP-analog (Fig. 3.4). 
The side-chain hydroxyl groups from switch I residues Thr35 and Tyr32 are flipped 
away from the solvent and make hydrogen bonds with the Mg2+ and the γ-phosphate, 
respectively. The Mg2+ ion has a hexavalent coordination geometry composed of the 
β- and γ-phosphates, as well as the Thr17 and Thr35 side-chain hydroxyl groups 
which provide four corners of a coordination plane with Mg2+ in the center while a 
water molecule is bonded to it on either side.  
As is the case with the structures for activated forms of Cdc42 bound to effectors, 
Phe37 within the Cdc42 (Q61L) – GMP-PCP complex has re-oriented in such a way 
as to allow for Thr35 to flip into position to coordinate the Mg2+ ion. Coordination of 
the Mg2+ by Thr35 is a hallmark of nearly all activated G protein structures. However, 
unlike the x-ray structures for Cdc42 (Q61L) – GMP-PNP bound to the limit-binding 
domain from Par6 (1NF3) or Cdc42 – GMP-PCP bound to the limit-binding domain 
of Pak6 (2ODB), Phe37 in the Cdc42 (Q61L) – GMP-PCP complex is in a different 
rotomeric conformation. These differences in conformations arise from specific 
interactions between Phe37 and the various effector proteins. In both the Cdc42 
(Q61L) – GMP-PNP – Par6 (1NF3) and Cdc42 – GMP-PCP – Pak6 (2ODB) 
structures, Phe37 is buried in a hydrophobic pocket composed of residues from the 
effector molecule as well as switch II residues from Cdc42 itself. 
Subtle differences in switch II are also observed between the ground-state Cdc42 
(Q61L) – GMP-PCP complex and the available x-ray structures for Cdc42  
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Figure 3.4 Switch I for the Cdc42 (Q61L) – GMP-PCP complex is in an identical 
conformation with those for Cdc42 bound to effector proteins. The hallmark of G 
protein activation is the movement of switch I toward the guanine-nucleotide where 
highly conserved switch I residues, Thr35 and Tyr32, can coordinate to the Mg2+ and 
γ-phosphate respectively. A structural alignment of the Cdc42 (Q61L) – GMP-PCP 
complex with the structures for the GTP-analog-bound form of Cdc42 in complex 
with the effector proteins Par6 and Pak6 reveals an identical switch I conformation. 
switch II between the Cdc42 (Q61L) – GMP-PCP and the Cdc42 – GMP-PCP – Pak6 
complexes is identical as well. Switch II in the Cdc42 (Q61L) – GMP-PNP – Par6 
complex is slightly shifted due to specific interactions with the effector protein.    
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bound to its effectors Par6 and Pak6 (1NF3, 2ODB). The overall fold of switch II 
amongst all three x-ray structures is virtually identical (i.e. a loop region (loop4) 
followed by a β-turn and helix α2). However, when compared to the structure for 
Cdc42 (Q61L) – GMP-PCP, the α2 helix in the Cdc42 (Q61L) – GMP-PNP – Par6  
complex is shifted by an average of ~1 Å overall with a maximum shift of 1.4 Å at 
Arg66 (Fig. 3.5A). The bulk of the changes occur between residues 60 – 75. 
Movement of α2 is mostly toward the bound effector protein which is hydrogen 
bonded to the switch II residue Tyr64 by the effector residue Asp149. The Cαs from 
Leu61 are 0.7 Å apart between the two structures with the residue from the Cdc42 – 
GMP-PNP – Par6-CBD complex closest to the nucleotide-binding pocket. 
Additionally, the side-chains are in opposite rotomeric conformations, having been 
rotated 180º about χ1. 
Likewise, comparisons between the Cdc42 (Q61L) – GMP-PCP and Cdc42 – 
GMP-PCP – Pak6 complexes reveal a slight shift of helix α2 with a maximum 
distance occurring at Gln74 of 1.54 Å (Fig. 3.5B). However, unlike the case for the 
Cdc42 (Q61L) – GMP-PNP – Par6 complex, Gly60 is not involved in any detectable 
position shift. Additionally, the β-turn, which is composed of residues G61EDY64, is 
nearly unchanged. Once again, the side-chain orientation of Gln61 from the Cdc42 – 
GMP-PCP – Pak6 complex is slightly altered relative to its position in the Cdc42 
(Q61L) – GMP-PCP complex, having been rotated about the χ1 bond by nearly 180º. 
Although the Cdc42 – GMP-PCP – Pak6 structure has the catalytically important 
Gln61, which is in a slightly different conformation compared to Leu61 in the Cdc42 
(Q61L) – GMP-PCP complex, it is not in position to hydrogen bond to the γ-
phosphate nor to any potential catalytic water molecule. 
Interestingly, one similarity between all three structures (i.e. Cdc42 (Q61L) – 
GMP-PCP, Cdc42 (Q61L) – GMP-PCP – Par6, and Cdc42 – GMP-PNP – Pak6) is the  
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Figure 3.5. Comparison of switch II between the effector-bound complexes for 
Cdc42 and the Cdc42 (Q61L) – GMP-PCP complex. A, Switch II for Cdc42 (Q61L) 
– GMP-PNP (green) bound to Par6 is slightly shifted toward the effector protein when 
compared to the ground-state conformation depicted in the Cdc42 (Q61L) – GMP-
PCP complex (orange). The bulk of the shift is caused by an interaction between 
switch II residue Tyr64 and an arginine residue from Par6. B, The interaction with 
Pak6 causes a slight shift in the C-terminal portion of the switch II helix when 
compared to the Cdc42 (Q61L) – GMP-PCP complex. Overall, these results indicate 
that these shifts in switch II are a result of specific interactions with the effector 
proteins and not the result of differences between the activated ground-states between 
the Cdc42 molecules.   
 
 
 
 
 
 
 
 
 100
  
 
 
 
 
 
 
 
 
 
 
Switch II
Y64
 
 
Switch II
Par6
Pak6
Cdc42 (Q61L)
Cdc42 – Pak6
               A. 
               B.  
 
 
 
 
 
 
 
 
 
 
 
 101
presence of a water molecule hydrogen bonded to the γ-phosphate of the nucleotide 
analog (Fig. 3.6A). This water molecule (Wat26, Wat511, Wat248 in the -Pak6, -Par6, 
and Cdc42 (Q61L) – GMP-PCP complexes respectively), occupies nearly the same 
coordinates and overlaps nicely with the position of the Gln61 carbamoyl group from  
the Cdc42 - GDP•AlF3 – Cdc42GAP complex (1GRN) (Fig. 3.6B). In the Cdc42GAP 
complex, Gln61 is observed making contacts to both the γ-phosphate and the attacking 
water molecule which is in position for an in-line SN2 type nucleophilic attack on the 
γ-phosphate. This is an important feature as it has been speculated that proper 
positioning of the water molecule by Gln61 is an important step in the hydrolysis 
mechanism of most G proteins (20-22). It is believed that the inability of G protein 
Q61L mutants to coordinate the attacking water molecule underlies their inability to 
hydrolyze GTP and to show constitutive signaling activity.  
 
Comparisons between Cdc42 (Q61L) – GMP-PCP and Cdc42 - GDP•AlF3 – 
Cdc42GAP 
 There are slight differences in the switch I conformation in the Cdc42 - 
GDP•AlF3 – Cdc42GAP complex (1GRN) versus the Cdc42 (Q61L) – GMP-PCP 
complex. These differences arise from the distinct interactions that occur between the 
GAP and switch I. Notably, Tyr32, which is in direct contact with the γ-phosphate in 
the Cdc42 (Q61L) – GMP-PCP complex, is pushed away from the phosphate and 
toward the solvent in the GAP structure (Fig. 3.7). This displacement is a consequence 
of the interaction between the so-called arginine finger (Arg305) from Cdc42GAP and 
the β and γ-phosphates from the nucleotide bound to Cdc42. Arginine 305, from 
Cdc42GAP, occupies the same position as Tyr32 in the Cdc42 (Q61L) – GMP-PCP 
complex. As a result of the reorientation of Tyr32 in the Cdc42 – GDP•AlF3 – 
Cdc42GAP complex, switch I residues upstream of Tyr32 have been slightly  
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Figure 3.6 A-B. A water molecule is hydrogen bonded to the γ-phosphate in the 
Cdc42 (Q61L) – GMP-PCP complex as well as the Par6- and Pak6-bound Cdc42 
x-ray crystal structures. A, X-ray crystal structures for Cdc42 bound to either Par6 
(green), Pak6 (red), compared to the structure for the Cdc42 (Q61L) – GMP-PCP 
(orange) complex shows an equivalent water molecule hydrogen bonded to the γ-
phosphate in all cases. B, The water molecules from the three previous x-ray crystal 
structures occupy similar positions to Gln61 from the Cdc42 – RhoGAP complex 
(blue). Glutamine 61 is thought to help align a nucleophilic water molecule for an in-
line SN2 attack on the γ-phosphate during the transition state for GTP hydrloysis. The 
equivalent water molecules may represent the position of catalytic water prior to the 
transition state.       
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Figure 3.7. Switch I is slightly shifted in the x-ray crystal structure for the Cdc42 
– GDP●AlF3 – GAP complex versus the Cdc42 (Q61L) – GMP-PCP complex. 
Arginine 305 from the GAP protein pushes Tyr32 away from the γ-phosphate which 
causes slight disruptions to switch I at positions N-terminal to Tyr32 when compared 
to Switch I from the Cdc42 (Q61L) – GMP-PCP complex. However, Thr35 is still 
coordinated to the Mg2+ ion similarly in both structures. Additionally, switch II 
between the two structures is virtually identical.   
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reoriented as well. Although the main-chain atoms for Phe28, which is conserved in 
the Rho family of small G proteins, have been shifted along with other switch I 
residues, the side-chain aligns well and is able to provide a π-π orbital stabilization to 
the guanine-ring of GDP. The side-chain of Phe37 in the Cdc42 - GDP•AlF3 – 
Cdc42GAP complex is in a different rotomeric conformation than the one observed in 
the Cdc42 (Q61L) – GMP-PCP complex. As described earlier, the precise orientation 
of Phe37 can be specifically influenced by each individual effector, and in this case, 
by the regulator Cdc42GAP. 
 Surprisingly, switch II of the Cdc42 – GDP•AlF3 – Cdc42GAP complex is 
mostly unchanged when compared to the structure for the Cdc42 (Q61L) – GMP-PCP 
complex. One notable exception is the side-chain orientation of Gln61 in the Cdc42 – 
GDP•AlF3 – Cdc42GAP complex versus Leu61 in the Cdc42 (Q61L) – GMP-PCP 
complex. As mentioned above, Gln61 is observed facing toward the AlF3 moiety in 
the Cdc42GAP complex, and actually forms hydrogen bonds with AlF3 as well as with 
the purported catalytic water molecule which is in position for an in-line SN2 
nucleophilic attack, whereas glutamine 61 in the Cdc42 (Q61L) – GMP-PCP complex 
faces in the opposite direction (See Fig. 3.6B).  
 
31P-NMR studies of Cdc42-GMP-PCP and Cdc42 (Q61L) – GMP-PCP in the 
presence and absence of effector interactions 
 31P-NMR analysis of the Cdc42 – GMP-PCP complex showed that it existed in 
only one conformational state. Upon addition of an effector protein (the limit-binding 
domain from Pak3 called Pak3-PBD), there was an apparent transition to a distinct 
conformational state as depicted by a chemical shift in phosphate resonances from the 
nucleotide. This new conformational state most likely resembles the signaling-active 
state as represented in the effector-bound structures for Cdc42. The initial 
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conformational state (representing that seen in the absence of an effector protein), 
most likely is an intermediate state which closely resembles the signaling-inactive 
(GDP-bound) state. 
 In an attempt to see if there are any structural differences between the wild-
type Cdc42 – GMP-PCP and constitutively activated Cdc42 (Q61L) – GMP-PCP in 
solution, we again used 31P-NMR spectroscopy. Interestingly, the 31P-NMR spectra 
obtained for these two Cdc42 complexes were very similar. The resonance frequencies 
obtained for all three phosphate residues were virtually identical between the two 
complexes with the largest frequency shift (about 0.3 ppm) occurring at the γ-
phosphate (Fig. 3.8). After the addition of the effector protein (Pak-PBD), the wild-
type Cdc42 complex showed the characteristic up-field and down-field resonance 
shifts for the α- and γ-phosphates respectively, as reported previously (81). 
Surprisingly, however, the spectra for the Cdc42 (Q61L) – GMP-PCP – PBD complex 
revealed that the γ-phosphate peak had split into two peaks. The first and larger peak 
corresponded to the effector-free peak whereas the second smaller peak represented an 
unknown state. The α- and β-phosphate frequencies remained relatively unchanged 
compared to the effector-free spectra. 
 The splitting of the γ-phosphate peak implies an equilibrium of two states that 
interconvert slowly compared to the NMR time-scale. The first state, which is 
associated with the effector-free Cdc42 (Q61L) – GMP-PCP complex, likely 
represents the signaling-active structure that was observed in the x-ray crystal 
structure for the complex. This notion is borne out by the observation that the first γ-
phosphate peak is identical to the γ-phosphate peak in the effector-free spectra for 
Cdc42 (Q61L) – GMP-PCP. The second peak may represent a new conformational 
state, perhaps unseen in the x-ray crystallographic structures, that is most likely an 
outcome of the Q61L substitution. 
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Figure 3.8. The Cdc42 (Q61L) – GMP-PCP complex is in an activated 
conformation in solution as seen by comparison of the 31P-NMR spectras for the 
effector-free and effector-bound complexes. The spectra between Cdc42 – GMP-
PCP and Cdc42 (Q61L) – GMP-PCP are very similar. Only one peak for each 
phosphate is apparent indicating only one detectable conformation in solution. 
However, after addition of saturating amounts of an effector protein to the Cdc42 
(Q61L) – GMP-PCP complex, the γ-phosphate peak splits into two while the Cdc42 – 
GMP-PCP peak completely shifts upfield. The first peak for the Cdc42 (Q61L) – 
effector complex corresponds exactly to the peak position for the effector-free protein 
and is more populated than the second peak. The first peak most likely represents the 
activated structure as seen in the x-ray crystal structure while the second peak may 
represent an unknown intermediate.       
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31P-NMR Spectra for the Cdc42 (Q61L) – GTP complex 
It has been shown that different nucleotide analogs can sometimes affect the 
activation of G proteins in a distinct manner (10-12,23). In the case of Ras, the 
different nucleotide effects are observable mainly as differences in the 31P-NMR-
derived equilibria between two conformational states which are thought to correspond 
to an intermediate activated structure and a fully activated structure (12). In order to 
view what effect the physiologically relevant nucleotide (GTP) might have on 
structural activation, it was necessary to use the (Q61L) constitutively activated 
mutant form of Cdc42 to prevent hydrolysis over the course of the experiment. 
 Spectra for Cdc42 (Q61L) – GTP revealed only a single peak for each 
phosphate residue which is in agreement with the GMP-PCP data (Fig. 3.9). However, 
the peaks are much broader in the Cdc42 (Q61L) – GTP spectra compared to those for 
the Cdc42 – GMP-PCP spectra, indicating more flexibility in the protein’s 
conformation. The addition of Pak3-PBD at levels well above the Kd value for the 
interaction between Pak-PBD and Cdc42 (Q61L) – GTP revealed a similar splitting of 
the γ-phosphate peak as observed in the 31P-NMR spectra for the Cdc42 (Q61L) – 
GMP-PCP – PBD complex. The positions for the largest peaks were virtually 
unchanged compared to the effector-free spectra, indicating that the effector-free 
protein was in an activated conformation. Identical to the Cdc42 (Q61L) – GMP-PCP 
data, the second peak may represent a new conformational state distinctive to the 
Cdc42 (Q61L) mutant, which is in equilibrium with the activated conformation 
observed in the x-ray crystal structure for the Cdc42 (Q61L) – GMP-PCP complex.  
        
 
 
 111
  
 
 
 
 
 
 
 
Figure 3.9. GTP-bound versus GMP-PCP-bound Cdc42 (Q61L) reveals similar 
structural characteristics indicating the guanine-nucleotide-analog is a good 
mimic for cellular GTP. Comparisons between the 31P-NMR spectra for effector-
bound- and effector-free-Cdc42 (Q61L) – GTP reveal a similar pattern to the spectra 
for Cdc42 (Q61L) – GMP-PCP. The spectra for the GTP-bound protein is broader 
than the GMP-PCP-bound spectra which may indicate more flexibility in its 
conformation. Addition of an effector protein produces the γ-phosphate peak splitting 
observed for the GMP-PCP-bound Cdc42 (Q61L) spectra indicating both nucleotides 
behave similarly. Small errant peaks in both spectra most likely represent 
contaminating GDP and GMP moieties from the exchange process.   
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Discussion 
  
Comparing the x-ray crystal structure of the Cdc42 (Q61L) – GMP-PCP versus the 
Cdc42 – GMP-PCP complex 
 Previously, it was observed that the x-ray structure for the Cdc42 – GMP-PCP 
complex revealed a signaling-active conformation that resembled the signaling-
inactive state for the Cdc42 – GDP (1ANO) complex (16). Additional information was 
obtained from both fluorescence spectroscopic analysis as well as 31P-NMR studies 
which supported the x-ray structural findings. These results lead to the conclusion that 
Cdc42 – GMP-PCP is able to be molded by its effectors into a conformation that most 
likely resembles the conformational states seen in the NMR and x-ray structures of 
Cdc42 bound to effector proteins as well as to its regulator Cdc42GAP (6-8,18).  
 In light of these new findings, the question arose as to how the constitutively 
active Cdc42 (Q61L) mutant behaves and whether it would also require effector 
binding to mold it into a signaling-active conformational state. Thus we set out to 
solve the x-ray structure for the Cdc42 (Q61L) – GMP-PCP complex, and once again, 
obtained some rather unexpected results. 
 Switch I within the Cdc42 (Q61L) – GMP-PCP complex was rearranged to 
cover the nucleotide-binding pocket in much the same way as was observed in the 
Cdc42 – effector complexes. Unlike the structure for the Cdc42 – GMP-PCP complex, 
Tyr32 within the Cdc42 (Q61L) – GMP-PCP complex is hydrogen bonded to the γ-
phosphate while the side chain for Thr35 is in position to coordinate to the Mg2+ (Fig. 
3.1A-C). The remainder of the Cdc42 (Q61L) – GMP-PCP complex is virtually 
identical to the structure for Cdc42 – GMP-PCP, with only a slight movement in the 
position of some of the main-chain atoms in switch II. 
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 This fundamental difference in switch I between the two structures has 
interesting implications. However, it should first be noted that the switch I 
conformation, as observed in the x-ray structure for the Cdc42 – GMP-PCP complex, 
is most likely only visible due to crystal contacts that stabilize this conformation. In 
solution, it is likely that switch I can interchange between a number of conformational 
intermediates, some of which may closely resemble, but never actually assume the 
signaling-active conformational states exhibited by Cdc42 bound to its effectors as 
well as by the Cdc42 (Q61L) – GMP-PCP complex.  
Mutation of Gln61 to a leucine has apparently changed the energy landscape for 
Cdc42 (Q61L) – GMP-PCP so as to favor a conformation for switch I which is similar 
to that observed when Cdc42 is complexed with its effector proteins. The mechanism 
for this is unclear from the x-ray crystal structure. However, the answer most likely 
comes from a change in the thermodynamics of folding for the protein. One qualitative 
argument for how the Q61L mutation might work is by altering the free energy 
associated with the transition state of the switching mechanism so that the energy 
barrier required to reach a truly signaling-active conformational state has been 
reduced. This is exactly the same way an enzyme reduces the free energy associated 
with the transition state in a chemical reaction without altering the free energies of the 
reactants or products. A second possibility is that the transition state, as well as any 
intermediates along the conformational pathway, has been changed to a completely 
new set of conformations, so as to allow for the activated structure, as seen in the 
Cdc42 (Q61L) – GMP-PCP complex, to be energetically favored. These two 
possibilities are not mutually exclusive and in fact, the true mechanism may be a 
combination of the two. 
There is some evidence from the x-ray structures of Ras switch II mutants to 
support the idea that a point mutation can alter the final signaling-active structure. In 
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the x-ray structure for the Ras (G60A) – GMP-PNP complex, a previously 
undocumented rearrangement of switch II, beginning at Ala60 and ending at Arg68, is 
observed (24). While this finding may not have been very surprising, what was 
unexpected was the finding that switch I had undergone a significant rearrangement so 
that it was no longer coordinated to the nucleotide. In fact, Phe28, which in many 
small G proteins makes π-π stacking interactions with the guanine ring of the bound 
GDP molecule, was shifted by 13 Å toward the solvent. Threonine-35, which 
coordinates to the Mg2+ as well as to the γ-phosphate in nearly all GTP-bound G 
protein structures, was shifted away from the nucleotide and no longer interacted with 
either of its ligands. The switch I orientation for the Ras (G60A) mutant was most 
similar to that observed in the structure for nucleotide-free Ras complexed to its 
guanine nucleotide exchange factor SOS (son of sevenless) (25). 
Additionally, the x-ray structure for Ras (A59G) – GMP-PNP reveals a structure 
that has been suggested to represent an intermediate between the GDP- and GTP-
bound forms of wild-type Ras (26). Interestingly, the φ,ψ dihedral angles for residue 
59 are identical in both the Ras – GMP-PNP (5P21) and Ras (A59G) – GMP-PNP 
complexes. The main differences between the two structures are focused around 
switch II, specifically beginning at Gly60 and ending at Ser65. Switch II in the GMP-
PNP-bound Ras (A59G) mutant appears to assume a conformation that closely 
resembles an intermediate state between the GDP- and GTP-bound Ras structures as 
predicted by molecular dynamics simulations (27). Switch I reveals only subtle 
changes to the side chains of Tyr32 and Glu37 in the Ras (A59G) – GMP-PNP 
complex. Tyrosine-32 is observed to move closer to the nucleotide and to make a 
water-mediated hydrogen bond to the γ-phosphate while Glu37 is less solvent exposed 
due to the close proximity of Tyr71.  
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The idea behind the two Ras mutants described previously, (G60A) and (A59G), 
was to change the conformational freedom at a position long thought to be critical for 
the structural rearrangements that occur during the transition from GTP-bound Ras to 
the GDP-bound Ras. However, in both cases, the structure that emerged was altered 
from what has been observed in wild-type and other mutant structures for Ras (i.e. Ras 
(G12V), Ras (Q61L)) (9,28). In the case of the A59G mutant, the structural 
rearrangement was somewhat predictable in that it affected mostly just the switch II 
region. In the case of the G60A mutation however, switch I was unpredictably altered. 
What can be learned from these two structures is that a point mutation, within switch 
II, affected the conformational rearrangements that take place during the activation 
event to an extent that altered the final activated structure. These final structures were 
different from any known structures for activated Ras and as such, were easily 
distinguishable as being caused by the point mutation. In a similar manner, the Q61L 
point mutant may be affecting the final activated conformation but in a manner 
favoring a structure that is virtually identical to activated structures for Cdc42 bound 
to effector proteins.   
 
31P-NMR studies show that GMP-PCP induces similar conformational states within 
wild-type Cdc42 and the Cdc42 (Q61L) mutant 
   31P-NMR has proven to be a useful tool for investigating conformational 
equilibria of activated Ras in solution (12,29,30). Interestingly, crystal structures for 
activated forms of Ras have repeatedly shown a closed switch I conformation, denoted 
by Thr35 and Tyr32 being brought into close contact with the Mg2+ ion and the γ-
phophate group, respectively (3,4,28,31). However, the 31P-NMR spectra for Ras 
bound to GTP and various GTP analogs (GMP-PNP, GMP-PCP) in solution have 
revealed two conformational states in fast exchange, designated as states 1 and 2 
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(12,29). State 2 is slightly upfield of state 1 and has been shown to represent the 
activated structure of Ras as seen in the x-ray crystal structures. Addition of the Ras-
binding domain (RBD) of the Ras effector Raf –1 completely shifted the population of 
state 1 to state 2, thus supporting the idea that state 2 represents the fully activated 
structure. State 1 is thought to be an intermediate state that is characterized by the lack 
of key interactions between Thr35 and Tyr32, and Mg2+ and the γ-phosphate moiety, 
respectively. As indicated above, these interactions are the hallmarks of activated G 
protein structures and as such, it is likely that switch I is in a more open state, perhaps 
similar to the GDP-bound state. This has been borne out by experiments with the 
partial loss of function T35S mutant and the complete loss of function T35A mutant 
(30). 31P-NMR spectra for both mutants revealed only one conformation in solution 
corresponding to state 1 for wild-type Ras. However, upon addition of Raf-RBD, the 
Ras (T35S) mutant showed a second peak corresponding to state 2 whereas the Ras 
(T35A) mutant did not, implying a role for the methyl group from Thr35 in signaling.  
In an attempt to identify the structure of state 1, the x-ray crystal structure of the 
Ras (T35S) – GMP-PNP complex was solved (30). The structure revealed a lack of 
electron density for both switch regions, indicating a high level of mobility. Since state 
1 is shared by the Ras (T35A) mutant, the Ras (T35S) mutant, and wild-type Ras, it 
seems reasonable to assume that state 1 must be highly dynamic, and therefore lacks 
contacts to Mg2+ and the γ-phosphate of GTP or GTP-analogs. 
 Previously, we demonstrated that Cdc42, when bound to the non-hydrolyzable  
GTP-analogs GMP-PCP or GMP-PNP, exhibited only one conformational state in 
solution (16). This together with the x-ray crystal structure for the Cdc42 – GMP-PCP 
complex as well as the results from fluorescence studies performed in solution, 
suggests that, unlike the case for Ras, Cdc42 resides in state 1 almost exclusively. 
Furthermore, state 1 for GTP-bound forms of Cdc42 is most likely very similar, if not 
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identical, to the conformation for the GDP-bound state of the protein. Since the x-ray 
structure for the Cdc42 (Q61L) – GMP-PCP complex revealed a similar architecture 
to those determined from the structures for activated Cdc42 in complex with effector 
proteins, we were curious to see if the Cdc42 (Q61L) – GMP-PCP complex exhibited 
similar or different behavior in solution. Like the case for the Cdc42 – GMP-PCP 
complex, the 31P-NMR spectra for the Cdc42 (Q61L) – GMP-PCP complex revealed 
only one conformational state in solution (Fig. 3.8). Surprisingly, the addition of an 
effector caused a splitting of the γ-phosphate peak. One peak, the downfield peak at  -
7.7 ppm, was identical to the peak observed for the Cdc42 (Q61L) – GMP-PCP 
complex alone and will be referred to as state 1 hereafter. Additionally, a qualitative 
inspection of the relative areas under the two γ-phosphate peaks reveals that state 1 
appears to be more populated than state 2 (the upfield peak) indicating a greater 
proportion of the protein is in state 1, even after addition of the effector protein. 
 One possible explanation for the appearance of the two γ-phosphate peaks is 
that the Cdc42 (Q61L) – GMP-PCP – PBD complex was not at saturation. This would 
imply that upon saturation, the γ-phosphate peak would be completely shifted to the 
upfield position and thus disappear, similar to what occurred when the PBD was added 
to GMP-PNP bound to wild-type Cdc42. However, there are two pieces of evidence 
that argue against this. First, the spectra for the Cdc42 – GMP-PCP – PBD and Cdc42 
(Q61L) – GMP-PCP – PBD complexes were collected on the same day, in the same 
molar quantities, which were far in excess of their equilibrium dissociation constants 
(32,33). Since only one γ-phosphate peak was evident in the spectra for the Cdc42 – 
GMP-PCP – PBD complex, it seems likely that this complex had reached saturation. 
The same PAK-PBD protein stock was used in all of the experiments, which makes it 
unlikely that a significant portion of the protein had degraded in the intervening time 
between experiments.  
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Another possible explanation is that the affinities between the effector and the 
different forms of Cdc42 are different whereby Cdc42 (Q61L) has a lower affinity 
than Cdc42 wild-type for effector proteins. The apparent equilibrium dissociation 
constants (Kd) have been calculated for the interaction between PAK-PBD and GMP-
PNP bound Cdc42 and have been shown to be between 0.2 and 1 μM (32,33). Using 
the higher Kd of 1 μM, it can be calculated that the Cdc42 – GMP-PNP-PBD complex 
should be at saturation at the concentrations and conditions used in the experiment (i.e. 
1 μM protein each, pH 8.0). Additionally, it has been shown that the Cdc42 (Q61L) – 
GMP-PNP complex has a ten-fold higher affinity for PAK-PBD compared to GMP-
PNP-bound wild-type Cdc42, thus negating any difference in affinity between the two 
Cdc42 constructs as a possible explanation (32,33). In fact, the difference in affinity 
between the wild-type Cdc42 and the Cdc42 (Q61L) mutant supports our findings that 
GMP-PCP-bound wild-type Cdc42 requires interactions with effectors in order to 
achieve a fully activated conformation whereas the Cdc42 (Q61L) mutant does not. 
Conversely, our findings provide an explanation for the differences in affinities. 
Differences in the affinities between wild-type Cdc42 and the Cdc42 (Q61L) 
mutant for multiple effectors and regulators such as ACK, WASP, PAK, and RhoGAP 
have been shown to exist (34). In all cases, the Cdc42 (Q61L) mutant had a greater 
than ten-fold increase in binding affinity when compared to wild-type Cdc42. To see 
how our data helps to explain these differences between Cdc42 (Q61L) and wild-type 
Cdc42, it is helpful to look at the kinetic model that may describe the binding. In the 
simplest case, the bi-molecular interaction can be described as in equation 1 where 
CBD is the Cdc42 limit-binding domain for any effector and Cdc42* represents state 2 
as seen in the 31P-NMR spectra. 
 
CBDCdcCBDCdc K *42 *42 ⎯→←+     (1) 
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 In this case, Cdc42 is already in an activated conformation (Cdc42*) and the apparent 
Kd is defined only by the rates at which the two proteins associate and dissociate. 
However, based on our data, the model is slightly more complicated as depicted in 
equation 2. 
 
CBDCdcCBDCdc
CBDCdcCBDCdc
K
K
*42 *42
                             
4242  
3
24
1
KK
⎯→←+
↓↑
⎯→←+
↑↓    (2) 
 
In this model, we have added in the isomerization step for going from state 1 to state 
2. Since these experiments are performed under equilibrium conditions, all steps in the 
model are at equilibrium. Assuming that the isomerization step for the Cdc42 – GTP-
analog complex, when not bound to the effector protein, is extremely slow, we find 
that the reaction procedes almost exclusively through K1 and K2. Therefore the 
apparent Kd can be written explicitly as K1 * K2 * K3 which reveals that the overall 
affinity between Cdc42 and its effector protein has contributions from multiple steps 
in the pathway.  Relating this model to the model used in the literature to calculate the 
apparent Kd (see equation 1) (32-34), we see that there is only one equilibrium step 
which contributes to the overall affinity.  
However, according to our data, the case for Cdc42 (Q61L) is slightly different. 
The model for Cdc42 (Q61L) binding to effector may be expressed in a very similar 
manner to wild-type Cdc42 as in equation 3 below. 
 
CBDLQCdcCBDLQCdc
CBDLQCdcCBDLQCdc
K
K
*)61(42 *)61(42
                
)61(42)61(42  
3
2                                                                                       4
1
KK
⎯→←+
↑↓
⎯→←+
↓↑   (3) 
 121
 In this case, the equilibrium between state 2 and state 1 for activated Cdc42 (Q61L) is 
shifted greatly towards state 2 as denoted by the larger arrow pointing towards Cdc42 
(Q61L)*+CBD (represented by K4). In fact, it is almost a certainty that the equilibrium 
between states 1 and 2 (K4), before the binding of an effector, is significantly driven 
toward state 2 such that virtually the entire protein population exists in this state. In 
this case, equation 3 can be simplified to equation 4 which is the same bi-molecular 
binding model as seen in equation 1. 
 
CBDLQCdcCBDLQCdc K *)61(42 *)61(42 ⎯→←+    (4) 
 
By these new models, borne out of our data, it can be seen that the apparent Kd for 
wild-type Cdc42 binding to an effector protein would contain contributions from at 
least two additional steps, which is absent in the Kd calculated for Cdc42 (Q61L). It is 
likely that these extra steps account for the differences in the affinities between the 
Cdc42 isoforms and their effector proteins. 
 Overall, our findings highlight a fundamental difference between the 
constitutively active Cdc42 (Q61L) mutant protein and the wild-type Cdc42 protein. 
Based on the x-ray crystal structure for the Cdc42 (Q61L) – GMP-PCP complex we 
see that, unlike Cdc42 – GMP-PCP, the Q61L point mutation alters the 
conformational freedom of the protein so as to allow the Cdc42 (Q61L) mutant protein 
to assume a fully activated conformation in the absence of effector protein. 
Additionally, 31P-NMR experiments revealed that GMP-PCP-bound Cdc42 (Q61L) 
exists in only one state in solution. However, addition of Pak3-PBD revealed two 
distinct states. State 1 corresponds to the same state observed for the effector-free 
Cdc42 (Q61L) – GMP-PCP complex while the second state represents an unknown 
 122
activated state. Since state 1 is identical for both the effector-bound and effector-free 
complexes, we can deduce that state 1 is the activated state as seen in the x-ray crystal 
structure.  Furthermore, the physiologically relevant nucleotide, GTP, yielded similar 
results implying that the GTP-analog GMP-PCP does mimic GTP. Therefore, the 
structural effects we observe are not due to a difference in bound nucleotide.    
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 Chapter 4 
 
Conclusions 
 
  
Over the last 50 years, the field of cell signaling has made enormous strides 
towards understanding the basic principles which underlie how a cell interacts with its 
environment. One of the seminal discoveries in this field was the discovery of G 
proteins by Martin Rodbell and Alfred Gilman in the 1970s. At the very core of the 
problem Rodbell and Gilman were addressing was the question of how a hormone, on 
the outside of a cell, can induce a reaction across the membrane and affect intra-
cellular function. Thanks to their pioneering efforts, and those of their colleagues, we 
now know that many extracellular signals are transduced across the cellular membrane 
by a three component system comprised of a G protein coupled receptor (GPCR), a 
heterotrimeric G protein, and an effector protein. The effector protein typically 
changes the concentration of a second messenger molecule such as cAMP, as in the 
case for the adenylyl cyclase system, which is able to magnify the signal by regulating 
the functions of various downstream proteins. 
However, GPCRs are not the only cell surface receptors able to activate G 
proteins and initiate signaling cascades. Receptor tyrosine kinases (RTK) are also able 
to bind extra-cellular ligands and activate small G proteins, although indirectly. These 
small G proteins can control many of the major signaling pathways in the cell such as 
proliferation, apoptosis, differentiation, and cell motility. The most famous example of 
small G protein signaling involves the actions of Ras, a small G protein which is 
mutated in ~ 30% of all human cancers.  
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Common to all G proteins is the fact that they are switched “on” by binding 
GTP and switched “off” by hydrolyzing GTP to GDP and Pi. This G protein GTP 
binding and hydrolytic cycle is typically tightly regulated by both GEF and GAP 
proteins, for the small G proteins, and GPCR and RGS proteins for the heterotrimeric 
G proteins.  
It was revealed through x-ray crystallographic studies on Ras, as well as the 
heterotrimeric Gα subunit transducin, that activation of the G protein by binding GTP 
caused a structural rearrangement in two loop regions designated Switch I and II (1,2). 
Subsequent x-ray crystal structures for various other G protein family members 
confirmed that indeed, all G proteins thus far investigated undergo some form of 
structural rearrangement in both Switch I and II upon activation by binding to GTP.  
Members of the Rho family of small G proteins, at first glance, appear to behave in 
a similar manner to all other G proteins. Numerous x-ray crystal and NMR structures 
for RhoA, Rac1, as well as Cdc42 have revealed significant rearrangements of the 
switch regions when comparing between the active and inactive forms of the proteins 
(3-7). However, activated structures for Cdc42 have only been reported in the 
presence of effector or regulator proteins (5,6,8,9). Considering these structures along 
with the activated structures for virtually all other G proteins thus far known, it would 
seem reasonable to assume that the structure for Cdc42 bound to a GTP-analog 
complex would be identical to the structures for GTP-bound Cdc42 in complex with 
an effector protein. In fact this is not the case at all. Surprisingly, as we show in 
Chapter 2, the structure for Cdc42 bound to the GTP-analog GMP-PCP is virtually 
identical to that for the signaling-inactive Cdc42 – GDP complex (1ANO). 
One of the structural hallmarks of G protein activation is the coordination of the 
Mg2+ ion by a highly conserved threonine residue located within Switch I. A second 
hallmark is the movement of another highly conserved Switch I tyrosine residue into 
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close proximity to the γ-phosphate of the GTP moiety. The interaction of these two 
Switch I residues with the nucleotide lock the protein into the active conformation. In 
the signaling-inactive GDP-bound conformation (pdb id 1ANO), both Thr35 and 
Tyr32 face away from the nucleotide into solvent. As reported in Chapter 2, this is 
also the case for the signaling-active Cdc42 – GMP-PCP complex. 
This conformation presents an interesting question; how does an effector protein 
recognize and bind with high specificity to the GTP-bound state and not the GDP-
bound state? The first clue to answering this question comes from the structures of 
activated Cdc42 in complex with its effector proteins (5,6). These complexes reveal 
Switch I in Cdc42 to be in an activated state as noted by Thr35 and Tyr32 being 
brought into close proximity to the Mg2+ and γ-phosphate respectively. This indicates 
that binding of an effector protein drives the conformation of Cdc42 toward the active 
structure in a similar manner to the theory of induced fit put forward for enzyme-
substrate reactions (10). 
To test this hypothesis, we used a combination of fluorescence and 31P-NMR to 
view changes in Cdc42 before and after the activation event as well as before and after 
its binding to an effector protein. Fluorescence studies, whereby Tyr32 was replaced 
by a tryptophan residue, revealed that upon binding GTP, Cdc42 undergoes a 
relatively small change (an ~10% reduction) in its intrinsic tryptophan fluorescence 
when compared to the case for Ras. However, addition of the limit-binding domain for 
the Cdc42 effector Pak3, caused a more significant reduction in tryptophan 
fluorescence (between 20-30%) indicating the effector protein is able to drive the 
GTP-analog-bound Cdc42 into a different structural state. In agreement with the 
fluorescence data, 31P-NMR revealed that GTP-analog-bound forms of Cdc42 resided 
in only one detectable conformational state in solution at 5ºC. After addition of an 
equal molar amount of PBD, the first state was completely shifted to a second 
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conformational state which likely corresponds to the signaling-active conformation for 
Cdc42 as exhibited by various x-ray and NMR structures for Cdc42-effector 
complexes. When compared to 31P-NMR data for Ras, a clear difference is observed. 
Activated Ras exists in two states in solution, that have been designated states 1 and 2. 
In the absence of an effector protein, state 2 is typically more populated than state 1. 
After addition of an effector protein, the population of state 1 is completely shifted to 
state 2 which corresponds to the signaling-active structure for Ras. Based on these 
results, it is clear that in solution, GTP-bound forms of Ras exist predominately in an 
activated state (state 2) which is in equilibrium with another state (state 1) that is 
thought to resemble a signaling-inactive state. Addition of an effector protein 
stabilizes the activated state so that state 1 effectively disappears. Conversely, GTP-
bound forms of Cdc42 reside exclusively in a single state that, based on the x-ray 
crystal structure for the Cdc42 – GMP-PCP complex, is identical to the signaling-
inactive GDP-bound state. Addition of effector proteins then drives the formation of 
the signaling-active conformational state as depicted in the effector-bound structures 
for Cdc42. 
Overall, these findings suggest that rather than a single universal model for G 
protein activation, where GDP-GTP exchange, alone, is sufficient to induce the 
signaling-active state, there instead exists a spectrum of nucleotide-dependent 
conformational states for different G proteins ranging from a signaling-inactive state 
to a fully signaling-active conformation. Cdc42 represents one extreme of this 
spectrum, such that GDP-GTP exchange, alone, is not capable of inducing the 
signaling-active state, but rather the binding of effector proteins are required to 
achieve a fully activated conformation. Ras, on the other hand, represents the other 
extreme whereby the binding of GTP is sufficient to drive the structural 
rearrangements associated with the G protein activation event. 
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In Chapter 3 we address the question of whether the constitutively activated form 
of Cdc42 (Q61L) also requires an effector protein to drive it to the fully activated 
state. Glutamine 61 (Cdc42 numbering) is a highly conserved Switch II residue that is 
critical for GTP hydrolysis, even in the presence of a GAP (11). Similar to the case for 
GTP-analog bound forms of wild-type Cdc42, until now there has not been a high 
resolution structure for the GTP-analog-bound forms of Cdc42 (Q61L). This raises the 
possibility that the Q61L version of Cdc42 also requires effector protein interactions 
to achieve the fully activated state. Surprisingly, we found that the x-ray crystal 
structure for the Cdc42 (Q61L) – GMP-PCP complex was infact in a fully activated 
conformation, unlike the wild-type Cdc42 – GMP-PCP complex. Alignment of the 
Cdc42 (Q61L) – GMP-PCP complex with the structures for GTP-analog bound forms 
of Cdc42 complexed to effector proteins reveals a Switch I architecture which is 
virtually identical. In particular, Switch I within the Cdc42 (Q61L) – GMP-PCP 
structure has shifted so as to cover the nucleotide binding pocket, allowing Thr35 and 
Tyr32 to coordinate directly to the Mg2+ and γ-phosphate. 
Subsequently, 31P-NMR experiments of Cdc42 (Q61L) – GMP-PCP in the absence 
of an effector revealed only one conformational state in solution at 5ºC, similar to 
what we had observed for GTP-analogs bound to wild-type Cdc42. However, upon 
addition of saturating amounts of an effector (PBD), two conformational states were 
observed. The first state (state 1) corresponded exactly with the chemical shifts for 
Cdc42 (Q61L) – GMP-PCP alone. Furthermore, state 1 was more populated than state 
2 indicating that state 1 most likely represents the fully activated conformation 
observed in the x-ray crystal structure. State 2 on the other hand, may represent a 
distinct conformational state that is either specific to the Q61L point mutant, or 
because the interconversion between this state and state 1 is sufficiently slowed for us 
to observe it. 
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These findings are interesting because they offer an explanation to an observation 
made in the Lowe lab at Cambridge regarding the differences in binding affinities for 
wild-type Cdc42 and the Cdc42 (Q61L) mutant (12,13). Lowe and colleagues 
observed that Cdc42 (Q61L) had at least a 10-fold higher affinity for effector and 
GAP proteins than wild-type Cdc42. Based on our observations, these differences in 
affinity can be explained by the fact that wild-type Cdc42 needs first to bind to an 
effector protein and then isomerize into a fully activated structure. The binding 
constant for wild-type Cdc42 would contain contributions from multiple steps whereas 
Cdc42 (Q61L), which is already in a fully activated state, can be described by a single 
binding step. 
Cdc42 illustrates the importance for thorough examination of all G proteins 
individually. It is highly unlikely that Cdc42 is the only G protein to utilize a slightly 
different activation mechanism than Ras and provides evidence for a spectrum of 
activating mechanisms for G proteins. In fact, recently, an activated structure for M-
Ras in which Switch I has moved further away from the nucleotide binding pocket 
instead of closer to it, has recently been published (14). The results obtained with 
Cdc42 may require a new way of thinking about the activation of small G proteins, 
whereby the binding of GTP may or may not be sufficient to drive a G protein toward 
a fully activated structure. In the future, it will be interesting to see whether small G 
proteins related to Cdc42, such as Rac and TC10, behave in a similar manner and rely 
heavily on effector proteins to reach their fully activated conformational state. It also 
will be of interest to see why the Q61L mutation leads to a fully activated state and if 
other mutations that result in constitutive activation, like G12V and F28L, do the 
same.   
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